Poster Program in Build Stage through July 31, 2026 MSACL 2026 : Conference Program Montréal, Canada • October 4-9, 2026 Log In to Personalize Agenda Log In Enter the email address on your MSACL profile to receive your login link. Cancel Sending email, please wait... Abstract Clinical Use Status Key = Discovery stage. (58.93%, 2026) = Translation stage. (24.40%, 2026) = Clinically available. (16.67%, 2026) SUN Early Check-In Short Courses MON Early Check-In Short Courses TUE Short Courses Workshops Award Plenaries WED Ind Workshops Plenary Sci Sessions Posters Disc Grps THU Disc Grps Petite Suites Plenary Sci Sessions Posters FRI Fun Run/Walk Breakfast Closing Seminar ALL View All Posters View Abstracts by Topic Artificial IntelligenceBreath Analysis and VOCCases in Clinical AnalysisCases of Unmet Clinical Needs Data AnalyticsEmerging TechnologiesGlycomicsInformaticsLipidomicsMetabolomicsMicrobiologyMulti-omicsPre-AnalyticsPrecision MedicineProteomicsSpatialomicsTox / TDM / EndocrineVarious OTHER View Abstracts by Presenter Auray-Blais, ChristianeBoeuf, AmandineChai, YuboChen, MichaelCho, Sung-EunCrawford, MatthewDee, StacyDemeuse, JustineFontes, JessicaFoy, BrodyGatein, JustineGlunde, KristineGoss, NicolasHabler, KatharinaHartmann, HeatherHau, KevinHill, JaneHorkovics-Kováts, Gabriel StefanIaboni, NatashaJamzad, AmoonKandala, KeervaniKarin, AmirKubiniok, PeterKyle, PatrickLuna, Jose MarcioManeta-Stavrakaki, StefaniaPoisson, Etienne LjoniPonzetto, FedericoPrentice, BooneRappold, BrianRay, JulieRexroad, GillianSchmauder, FelixSeeley, ErinSeferovic, MaximSpies, NicholasStefanuto, Pierre-HuguesTreger, Rebeccavan Eyk, JenniferVandenbroucke, KevinWahl, DanielYates, JohnYeung, PriscillaZirem, Yanis View Abstracts by Poster Session Poster Session 1 : Wed 9:15 - 10:30 Poster Session 2 : Wed 13:45 - 15:00 Troubleshooting : Wed 17:00 - 18:30 Poster Session 3 : Thu 10:00 - 11:15 Poster Session 4 : Thu 14:15- 15:30

Saturday

Saturday 1630 1730

Badge Pickup Happy Hour @ Foyer, Conference Level Registration and Help Desk open for Badge Pickup. Linger in the registration lobby with a drink to meet friends as they arrive and/or find a buddy for dinner out. 2697

Saturday 1730 2030

Dinner On Own @ Your Choice Timeout Market (open till 10pm) is a good balance of proximity, ease and quality -- and a great option if flying solo. MSACL recommendations. Note that MSACL Reg Desk will be closed during this time, MSACL Staff need to eat, too. ;) 2778

Saturday 2030 2130

Badge Pickup Night Cap @ Foyer, Conference Level Registration and Help Desk open for Badge Pickup. Linger in the registration lobby with a drink to meet friends as they arrive. 2779

Sunday

Sunday 730 1930

Registration + Help Desk @ Foyer, Conference Level Open for Badge Pickup 2535

Sunday 745 900

Breakfast @ Montreal 1-3 Pick-up your badge on the conference level then find breakfast, prior to your Short Course, in the room adjacent to the reg desk (Montreal 1-3) where you can touch base with other attendees. 2536

Sunday 840 1200

LC-MSMS 202 : Data Driven LC-MS Troubleshooting @ Montreal 5 Will Thompson, PhD Move Analytical Cofounder, Move Analytical LLC in 2025. Principal Scientist and Director of Life Science Business Development at 908 Devices Inc, from 2021-2025. Assistant Director of the Proteomics and Metabolomics Shared Resource at Duke School of Medicine from 2007 to 2021. Relevant Financial Disclosures (within past 24 months, reported on Apr 22, 2026) Ownership Interest Move Analytical LLC Susan Abbatiello, PhD Northeastern University Susan Abbatiello earned a B.A. in Chemistry at The College of the Holy Cross. She worked for 5 years at Genetics Institute (Andover, MA) in the Biopharmaceutical Characterization and Analysis group before returning to graduate school. Susan earned her Ph.D. in Analytical Chemistry at the University of Florida, working under advisement of Drs. John Eyler and Nigel G. J. Richards, focusing on the quantitation of a protein suspected to play a role in drug-resistant acute lymphoblastic leukemia. Susan worked as a post-doc in the Clinical Proteomics facility at the University of Pittsburgh for Dr. Thomas P. Conrads, where she continued efforts in targeted proteomics research with a focus on cancer. In 2008, Susan moved to the role of Scientist in the Proteomics Platform at the Broad Institute (Dr. Steven Carr), where she served as co-chair of the NCI CPTAC (National Cancer Institute Clinical Proteomics Technology Assessment for Cancer) working group to evaluate stable isotope dilution selected reaction monitoring for the quantitation of plasma proteins related to cancer. In 2014, Susan transitioned to the role of Triple Quadrupole Product Specialist at Thermo Fisher Scientific and took on the responsibilities of FAIMS Product Manager in 2015. In 2018, Susan transitioned to the role of Executive Director of the Barnett Institute for Chemical and Biological Analysis, overseeing the Mass Spectrometry Core Lab. In 2020, she accepted the position of Interim Director of the Barnett Institute, while continuing the MS Core Lab responsibilities. Susan’s research interests include evaluation and making improvements in technologies for the targeted analysis and detection of biomarker candidates in blood, tissue, and cell samples. Her efforts have focused on improving accessibility and performance of mass spectrometric technologies and software, to help broaden its impact in basic, biomedical, and analytical research. Her work has resulted in over one dozen peer-reviewed publications as well as invited presentations at national conferences. Susan has been a member of ASMS since 2002. She has participated in poster abstract evaluation and has organized and chaired oral sessions and served on the program committee for ASMS Conferences. Susan has been a short-course instructor for the ASMS short course “Practical LC-MS Troubleshooting and Maintenance” since 2013. She served as the Vice President of Arrangements for ASMS from 2017-2019. Susan is also a member of ACS, is a reviewer for Analytical Chemistry, Journal of Proteome Research, Nature, and is currently on the Editorial Board of Molecular & Cellular Proteomics. On a personal note, Susan has been married to Russell Abbatiello for 23 years and they have a 10 year old daughter, Madeline, and a 7 year old son, James. They enjoy dressing up for Halloween as a family affair, and have attempted to replicate characters from Frozen, The Incredibles, Toy Story 4, and Despicable Me. Relevant Financial Disclosures (within past 24 months, reported on Oct 07, 2025) Not yet reported. Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2753

Sunday 840 1200

Isotopes 101 : Modern Isotope Ratio Analysis for Biomedical Research and Clinical Diagnostics @ Montreal 6 Cajetan Neubauer University of Colorado, Boulder The frontiers of metabolomics & proteomics are finally merging with isotope ratio mass spectrometry, opening exciting new opportunities in our understanding of biological systems. My lab at the University of Colorado Boulder helps pioneer related novel molecular measurements based on soft-ionization isotope ratio mass spectrometry. These advances can be used to study natural stable isotope fingerprints in metabolites, drugs, or small inorganic ions for a fascinating range of cross-disciplinary applications in life and earth sciences. To achieve our longterm goal of making natural isotope patterns universally useful, we combine expertise in metabolomics and proteomics with advanced concepts of high precision stable isotope analysis from geochemistry. Relevant Financial Disclosures (within past 24 months, reported on Jan 14, 2026) No relevant financial relationship(s) to disclose. Dwight Matthews, Ph.D. University of Vermont Prof. Matthews received his PhD degree in 1977 in Analytical Chemistry from Indiana University with a focus in mass spectrometry. For his Ph.D. thesis he developed the first gas chromatograph-combustion-isotope ratio mass spectrometer (GC-C-IRMS). He then began his career at Washington University School of Medicine in St. Louis in the Department of Medicine where he developed stable isotope tracer methods to study in vivo amino acid metabolism in humans centered around gas chromatography-mass spectrometry (GC-MS). Several of these methods are commonly used by investigators today. In 1986 he moved to Cornell University Medical College in New York City as a tenured Associate Professor of Biochemistry in Medicine and Surgery to continue studies of metabolism. Here his focus broadened to include studies of metabolism in conditions found commonly in surgical metabolism and energy metabolism using doubly labeled water measured by IRMS. He also directed the Core Laboratories of the General Clinical Research Center. In 1996 he moved to the University of Vermont (UVM) as a Professor of Medicine in the College of Medicine and as a Professor of Chemistry in the College of Arts and Sciences. At UVM he directed core laboratories related to mass spectrometry for the Clinical Research Center, the Vermont Genetics Network Proteomics Core Laboratory, and the Mass Spectrometry Core Laboratory in Immunobiology. During this period, he developed new proteomics methods using liquid chromatography-mass spectrometry (LC-MS) with a focus on precise measurement of stable isotopic enrichments in proteins and peptides. From 2002-2014, he was Chair of the Department of Chemistry at UVM and named the Pomeroy Professor of Chemistry. In 2019, Matthews became a Professor Emeritus of Chemistry and Medicine at UVM, but continues his research activities. Professor Matthews is a world-renown expert in the development of stable isotope tracer techniques to study metabolism in humans. He has published over 175 papers in a range of peer-reviewed journals and over 75 contributions to symposia and chapters in books, and has an H-index of 85. Relevant Financial Disclosures (within past 24 months, reported on Jan 14, 2026) No relevant financial relationship(s) to disclose. Anna Bitzer, B.S. Mayo Clinic My scientific and educational background is in chemistry and laboratory science. I earned a Bachelor of Science degree in chemistry from Hamline University in Saint Paul, MN. Shortly after, I began working for the clinical Metals Laboratory at Mayo Clinic where I was introduced to and quickly became fascinated with Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and the world of metals analysis in biological samples. Since then, I have worked my way up in the Metals Laboratory to a senior developer position, where I have gained experience developing and helping implement many laboratory developed tests (LDTs) on various ICP-MS platforms. I believe that multidisciplinary research is the key to meaningful scientific breakthrough, and am lucky to have the opportunity to collaborate with colleagues across departments at Mayo Clinic on research projects, conference presentations, and publications. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) No relevant financial relationship(s) to disclose. Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Total Contact Hours: 6.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2763

Sunday 840 1200

LC-MSMS 101 : Getting Started with Quantitative LC-MSMS in the Diagnostic Laboratory @ Montreal 7-8 Deborah French, PhD, DABCC (CC, TC), FADLM UCSF Deborah French Ph.D., DABCC (CC, TC), FADLM is a Director of Chemistry and the Director of Mass Spectrometry at the University of California San Francisco Health Clinical Laboratories. Her work currently focuses on the development and validation of LC-MS/MS assays for small molecules, specifically therapeutic drug monitoring, steroid hormones and toxicology. Deborah received her Ph.D. in biochemistry from the University of Strathclyde in Glasgow, Scotland and then completed a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, TN. She subsequently completed a ComACC Clinical Chemistry postdoctoral fellowship under the direction of Dr Alan Wu at the University of California San Francisco and is now board certified in Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Consultant Fees ARK Diagnostics, Roche Diagnostics (ended) Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. After fellowship, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. Next, she briefly served as a Lab Director for a small reference laboratory in PIttsburgh, PA. She then joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation. Relevant Financial Disclosures (within past 24 months, reported on Mar 08, 2026) No relevant financial relationship(s) to disclose. Grace van der Gugten, B.Sc. Chemistry Provincial Health Services Authority, BCCDC Toxicology Lab Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Mass Spectrometry Lab Scientist in the Toxicology Lab at the BCCDC in Vancouver, BC. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!). Relevant Financial Disclosures (within past 24 months, reported on Mar 05, 2026) No relevant financial relationship(s) to disclose. Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2537

Sunday 900 1220

Short Course Coffee Breaks @ Montreal 1-3 2780

Sunday 900 1220

Leadership 101 : Clinical MS Quality Improvement, Regulations, and Risk Management in Action @ Outremont 3 Melissa Budelier, PhD TriCore Reference Laboratories Dr. Budelier is the Section Chief and Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. She is also the CLIA laboratory director of TriCore's core laboratory. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Committee/Board/Advisory Board Roche Diagnostics, Greiner Bio-one, Siemens- Healthineers Royalty / IP / Other Income Washington Univ - Patents (Methods for Detecting Neurofilament Light Chain in Plasma and Cerebrospinal Fluid; Multiplexed Assay for Amyloidosis Disorders); Tech licensed by WashU to C2N Dx Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Alejandro Molinelli, PhD St. Jude Children's Research Hospital Alejandro Molinelli, PhD is Director of the Clinical Pharmacokinetics Laboratory in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children's Research Hospital. His duties include clinical consultancy, technical and regulatory oversight of the laboratory, and method development and validation. Dr. Molinelli also serves as a Clinical Chemist Consultant with the Department of Pathology at St. Jude. Prior to joining St. Jude Dr. Molinelli completed a Clinical Chemistry Fellowship at the University of Washington in Seattle; obtained his PhD in toxicology at the University of North Carolina at Chapel Hill; and bachelor’s and master’s degrees in biology and biochemistry at the University of Puerto Rico. Dr. Molinelli’s professional interests include therapeutic drug monitoring, clinical toxicology, and quality improvement. Relevant Financial Disclosures (within past 24 months, reported on Feb 03, 2025) No relevant financial relationship(s) to disclose. Prof. Dr. med. Michael Vogeser University Hospital, LMU Munich Dr. Michael Vogeser, MD, is specialist in Laboratory Medicine and senior physician at the Hospital of the University of the Ludwig-Maximilians-University Munich, Germany (LMU; Institute of Laboratory Medicine). As an Associate Professor he is teaching Clinical Chemistry and Laboratory Medicine. The main scope of his scientific work is the application of mass spectrometric technologies in routine clinical laboratory testing as translational diagnostics. Besides method development in therapeutic drug monitoring and endocrinology a further particular field of his work is quality and risk management in mass spectrometry and in clinical testing in general. Michael has published >240 articles in peer reviewed medical journals. Michael heads the Commission for In Vitro Diagnostics in the German Association of Scientific Medical Societies (AWMF).) Relevant Financial Disclosures (within past 24 months, reported on Mar 30, 2026) Not yet reported. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2728

Sunday 900 1220

Data Science 101 : Breaking Up with Excel and Rebounding with R and Claude @ Outremont 5 Daniel Holmes, MD, FRCPC St. Paul’s Hospital Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Honorarium/Expenses Novo Nordisk (ended) Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Nicholas Spies, MD University of Utah, ARUP Laboratories Nick Spies, MD, is a bioinformatician-turned-laboratorian who is a medical director in the Applied Artificial Intelligence group within ARUP laboratories' Division of Research and Innovation. He is focused on applying analytical techniques to improve the way we detect laboratory errors, and hopes to spread the good word of data science and machine learning within the laboratory medicine community. Relevant Financial Disclosures (within past 24 months, reported on Apr 30, 2026) Not yet reported. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2701

Sunday 900 1220

Data Science 203 : Machine Learning : A Gentle Introduction @ Outremont 6 Stephen Master, MD, PhD, FADLM Children's Hospital of Philadelphia Stephen Master received his undergraduate degree in Molecular Biology from Princeton University, and subsequently obtained his MD and PhD from the University of Pennsylvania School of Medicine. After residency in Clinical Pathology at Penn, he stayed on as a faculty member with a research focus in mass spectrometry-based proteomics as well as extensive course development experience in bioinformatics. After time as an Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine in New York City, where he served as Director of the Central Lab and Chief of Clinical Chemistry Laboratory Services, he took a position at the Children's Hospital of Philadelphia as Chief of Lab Medicine. One of his current interests is in the applications of bioinformatics and machine learning for the development of clinical laboratory assays. He would play with R for fun even if he weren't getting paid, but he would appreciate it if you didn't tell that to his department chair. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Committee/Board/Advisory Board Roche Diagnostics (ended), Indigo BioAutomation, Abbott Diagnostics Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Randall Julian, PhD Indigo BioAutomation Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to automatically analyze data from laboratories world-wide. Indigo's technology also drives new stand-alone medical devices, bringing advanced data analysis to every level of the clinical lab. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds Indigo BioAutomation, Inc. Salary Indigo BioAutomation, Inc. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2700

Sunday 900 1220

Data Science 301 : Intro to Deep Learning : From Neurons to Transformers @ Outremont 7 Lixing Song, Ph.D. Indigo BioAutomation, Inc Lixing currently serves as an Associate Professor in the Department of Computer Science and Software Engineering at Rose-Hulman Institute of Technology. He also works as a Research and Development Engineer at Indigo BioAutomation Inc. His primary research centers on foundational AI model applications for scientific data. His past research experience spans a variety of domains, including wireless networking, autonomous vehicles, and data-driven multidisciplinary research. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Salary Indigo BioAutomation, Inc. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2734

Sunday 1220 1420

Short Course Lunch Break @ Your Choice Your choice! This non-MSACL sponsored meal break is your chance to explore the culinary delights within the city of Montreal. MSACL recommendations. Timeout Market is a good balance of proximity, ease and quality -- and a great option if flying solo. 2784

Sunday 1400 1740

Short Course Coffee Breaks @ Montreal 1-3 2781

Sunday 1420 1740

LC-MSMS 203 : Validation of Quantitative LC-MS/MS Assays for Clinical and Academic Use @ Montreal 4 Claire Knezevic, PhD Lurie Childrens Hospital Dr. Claire Knezevic is a clinical chemist in the Department of Pathology and Laboratory Medicine at Lurie Children's Hospital with a focus on chemistry, point-of-care testing, quality improvement, drug monitoring, and personalized medicine. She is an Associate Professor in Northwestern's Feinberg School of Medicine in the Department of Pathology. Her interests include all things small molecule, from toxicology to therapeutic drug monitoring and their impacts on clinical care. Relevant Financial Disclosures (within past 24 months, reported on Mar 06, 2026) No relevant financial relationship(s) to disclose. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Hsuan-Chieh (Joyce) Liao, PhD, DABCC University of Washington Dr. Joyce Liao was a medical laboratory scientist in the newborn screening lab and obtained her Ph.D. degree in Clinical Medicine. She completed postdoctoral fellowship training in Clinical Chemistry at the University of Washington and Seattle Children’s Hospital. She is a board-certified Clinical Chemist and now serves as Chemistry Director at Harborview Medical Center. She continues to focus on the translation of the analytical power of mass spectrometry to real clinical applications. Her interests include toxicology, mass spectrometry, and laboratory utilization. Relevant Financial Disclosures (within past 24 months, reported on Sep 23, 2025) No relevant financial relationship(s) to disclose. Joshua Hayden, PhD, DABCC, FACB Cleveland Clinic Joshua is currently the Section Head of Clinical Biochemistry at Cleveland Clinic. He earned his PhD in chemistry from Carnegie Mellon University. He conducted postdoctoral research at Massachusetts Institute of Technology before completing a two-year clinical chemistry fellowship at University of Washington and 4 years as Assistant Professor at Weill Medical College. Joshua has special expertise developing and overseeing mass spectrometry assays in the clinical laboratory. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Honorarium/Expenses Thermo (speaker) Committee/Board/Advisory Board BioPorto (ended) Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2550

Sunday 1420 1740

LC-MSMS 202 : Data Driven LC-MS Troubleshooting @ Montreal 5 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2754

Sunday 1420 1740

Isotopes 101 : Modern Isotope Ratio Analysis for Biomedical Research and Clinical Diagnostics @ Montreal 6 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Total Contact Hours: 6.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2580

Sunday 1420 1740

LC-MSMS 101 : Getting Started with Quantitative LC-MSMS in the Diagnostic Laboratory @ Montreal 7-8 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2698

Sunday 1420 1740

Automation 201 : Streamlining Clinical Analysis through Efficient Workflow Integration @ Westmount 4 Evan McConnell, PhD Labcorp Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds Labcorp Salary Labcorp Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Matthew Campbell, PhD Labcorp Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Salary Labcorp Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2552

Sunday 1440 1800

Sample Prep 101 : Sample Preparation and Alternative Matrices for LC-MS Assays @ Outremont 1 William Clarke, PhD, MBA, DABCC Johns Hopkins University School of Medicine Dr. Clarke received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he remained at Johns Hopkins, where he is a Professor in the Department of Pathology, as well as the director of Point-of-Care Testing, Reference Toxicology, and Phlebotomy for the hospital. He also serves as the Vice-Chair for Quality and Regulatory Affairs in the Department of Pathology. His research interests include clinical mass spectrometry, method development and evaluation for therapeutic drug monitoring, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management. Dr. Clarke has published as author or co-author over 170 peer-reviewed manuscripts or book chapters, and is the Co-Editor of the textbook Contemporary Practice in Clinical Chemistry. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Consultant Fees Roche Grant/Research Support Thermo Fisher, Danaher, Roche Committee/Board/Advisory Board Roche, Truvian Mark Marzinke, PhD, DABCC, FAACC Johns Hopkins University School of Medicine Dr. Mark Marzinke is Professor of Pathology and Medicine in the Johns Hopkins University School of Medicine. He is board-certified in Clinical Chemistry by the American Board of Clinical Chemistry. He serves as the Director of the General Chemistry Laboratory at the Johns Hopkins Hospital and the Clinical Pharmacology Analytical Laboratory within the Division of Clinical Pharmacology. Dr. Marzinke is Co-Principal Investigator (PI) of the HIV Prevention Trials Network (HPTN) Laboratory Center (LC) and is the Director of the Clinical Laboratory Core for the Johns Hopkins Center for AIDS Research. His primary research interests are in the areas of antiretroviral pharmacology, HIV prevention science, mass spectrometry, pharmacogenetics and precision medicine, and laboratory automation. Dr. Marzinke has an active research program and serves as a principal investigator (PI) or co-investigator on a number of grants. He has collaborated on research to better characterize the multi-compartment pharmacology of antiretroviral agents when administered using alternative drug delivery systems using liquid chromatographic-mass spectrometric approaches. He has published more than 180 peer-reviewed articles, and holds leadership positions in several societies. Relevant Financial Disclosures (within past 24 months, reported on Mar 06, 2026) No relevant financial relationship(s) to disclose. Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation IN PROCESS. Course Schedule Segment 1 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 2 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 3 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 4 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2725

Sunday 1440 1800

Leadership 101 : Clinical MS Quality Improvement, Regulations, and Risk Management in Action @ Outremont 3 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2729

Sunday 1440 1800

Data Science 101 : Breaking Up with Excel and Rebounding with R and Claude @ Outremont 5 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2540

Sunday 1440 1800

Data Science 203 : Machine Learning : A Gentle Introduction @ Outremont 6 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2538

Sunday 1440 1800

Data Science 301 : Intro to Deep Learning : From Neurons to Transformers @ Outremont 7 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2736

Sunday 1740 1930

Short Course Welcome Dinner @ Montreal 1-3 An informal dinner for Short Course attendees and sponsors. If you are arriving later because your course begins Monday morning, note that dinner will be served through 7:30pm, at the latest. 2542

Sunday 1930 2200

MSACL Networking Lounge @ Salon Bonaventure, Hotel Level All conference attendees are welcome to close out the evening. MSACL will host snacks and drinks (requires token - pick up tokens at the door or from MSACL Staff). Must be wearing your badge to attend (badge pick up closes at 7:30pm). Drinks will be available through 10:00pm. The Lounge includes a pleasant outdoor patio along a stream and among some small trees and shrubbery, which may be enjoyable should we have nice weather. Open to all conference registrants. 2703

Monday

Monday 730 1830

Registration + Help Desk @ Foyer, Conference Level Open for Badge Pickup 2544

Monday 745 900

Breakfast @ Montreal 1-3 Pick-up your badge on the conference level then find breakfast, prior to your Short Course, in the room adjacent to the reg desk (Montreal 1-3) where you can touch base with other attendees. 2545

Monday 840 1200

LC-MSMS 203 : Validation of Quantitative LC-MS/MS Assays for Clinical and Academic Use @ Montreal 4 Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2582

Monday 840 1200

LC-MSMS 202 : Data Driven LC-MS Troubleshooting @ Montreal 5 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2755

Monday 840 1200

Metabolomics 203 : Metabolomics from Data Collection to Data Analysis @ Montreal 6 Tim Garrett, PhD University of Florida College of Medicine Dr. Garrett has over 20 years of experience in the field of mass spectrometry spanning both instrument and application development. He received his PhD from the University of Florida, under Dr. Richard A. Yost, working on the first imaging mass spectrometry-based ion trap instrument. He has also developed MALDI-based approaches to analyze proteins in bacteria and small molecules in tissue specimens. His current interests include development of techniques and instrumentation for metabolomics science using LC-HRMS and translational work in diagnostics for dried blood spots. He is an Associate Professor in the Department of Pathology at the University of Florida, and Director for the Southeast Center for Integrated Metabolomics (SECIM). Relevant Financial Disclosures (within past 24 months, reported on Sep 11, 2025) No relevant financial relationship(s) to disclose. Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2762

Monday 840 1200

LC-MSMS 101 : Getting Started with Quantitative LC-MSMS in the Diagnostic Laboratory @ Montreal 7-8 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2555

Monday 840 1200

Automation 201 : Streamlining Clinical Analysis through Efficient Workflow Integration @ Westmount 4 Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2721

Monday 840 1200

Clinical Proteomics 202 : MS-based Precision Diagnostics by Molecular Protein Analysis @ Westmount 5 Renee Ruhaak, PhD LUMC Renee Ruhaak holds a PhD from the Leiden University Medical Center (LUMC, supervisor Prof. M. Wuhrer) and did a post-doc at UC Davis in the lab of Prof. C.B. Lebrilla prior to joining the department of Clinical Chemistry and Laboratory Medicine at the LUMC. She is currently an associate professor with a research focus on the application of mass spectrometry within the clinical setting. This entails both development and implementation of quantitative protein mass spectrometry, as well as the role of mass spectrometry in metrology and test standardization. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Grant/Research Support Octapharma Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2702

Monday 840 1200

Clinical Proteomics 201 : Clinical Proteomics @ Westmount 6 Christopher Shuford, PhD Labcorp Chris Shuford, Ph.D., is Associate Vice President and Technical Director for research and development at Laboratory Corporation of America in Burlington, North Carolina. Chris received his B.S. in Chemistry & Physics at Longwood University and obtained his Ph.D. in Bioanalytical Chemistry from North Carolina State University under the tutelage of Professor David Muddiman, where his research focused on applications of nano-flow chromatography for multiplexed peptide quantification using protein cleavage coupled with isotope dilution mass spectrometry (PC-IDMS). In 2012, Chris joined LabCorp’s research and development team where his efforts have focused on development of high-flow chromatographic methods (>1 mL/min) for multiplexed and single protein assays for clinical diagnostics. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds Laboratory Corporation of America Salary Laboratory Corporation of America Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. All relevant financial relationships have been MITIGATED. Andy Hoofnagle, MD, PhD University of Washington Dr. Hoofnagle's laboratory focuses on the precise quantification of recognized protein biomarkers in human plasma using LC-MRM/MS. In addition, they have worked to develop novel assays for the quantification of small molecules in clinical and research settings. His laboratory also studies the role that the systemic inflammation plays in the pathophysiology of obesity, diabetes, and cardiovascular disease. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Grant/Research Support Waters, Inc. Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation IN PROCESS. Cory Bystrom, PhD Ultragenyx Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds Ultragenyx Salary Ultragenyx Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2549

Monday 900 1220

Short Course Coffee Breaks @ Montreal 1-3 2782

Monday 900 1220

Sample Prep 101 : Sample Preparation and Alternative Matrices for LC-MS Assays @ Outremont 1 Course Schedule Segment 1 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 2 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 3 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 4 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2723

Monday 900 1220

Leadership 101 : Clinical MS Quality Improvement, Regulations, and Risk Management in Action @ Outremont 3 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2730

Monday 900 1220

Data Science 100 : Data Literacy @ Outremont 4 Shannon Haymond, PhD Northwestern University Feinberg School of Medicine My lab performs research and clinical testing using mass spectrometry methods, develops new assays, and applies data analytics to enable improved quality and efficiency. My computational pathology efforts are aimed at building the capacity for advanced data analytics in the department through innovations in infrastructure, education, and research to facilitate data-informed decision making for clinical care, operations, and quality assurance. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Committee/Board/Advisory Board Roche Diagnostics (ended) Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Patrick Mathias, MD, PhD University of Washington Patrick Mathias, M.D., Ph.D., is a board-certified clinical pathologist and Associate Director of Informatics for UW Laboratory Medicine. Lab medicine has large impact on the general practice of medicine. It is key to correctly diagnosing diseases and selecting the right treatments for patients. Dr. Mathias's goal is to combine technical and medical knowledge to fulfill the triple aim--reduce the per capita cost of health care, improve the health of populations and most importantly improve the patient experience of care. Dr. Mathias earned his M.D. and Ph.D. from the University of Illinois. His clinical and research interests include clinical informatics, clinical chemistry and molecular diagnostics. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds Amgen, Corcept Therapeutics, Monte Rosa Therapeutics Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2750

Monday 900 1220

Data Science 101 : Breaking Up with Excel and Rebounding with R and Claude @ Outremont 5 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2551

Monday 900 1220

Data Science 203 : Machine Learning : A Gentle Introduction @ Outremont 6 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2547

Monday 900 1220

Data Science 301 : Intro to Deep Learning : From Neurons to Transformers @ Outremont 7 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2733

Monday 950 1200

Lipidomics 101 : Mass Spectrometry-based Lipidomics and Clinical Applications @ Westmount 2 Anne K. Bendt, PhD Singapore Lipidomics Incubator (SLING), National University of Singapore Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Deputy Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization. Relevant Financial Disclosures (within past 24 months, reported on Mar 05, 2026) No relevant financial relationship(s) to disclose. Amaury Cazenave Gassiot, PhD Singapore Lipidomics Incubator (SLING) and Department of Biochemistry, National University of Singapore Research Assistant Prof. Cazenave-Gassiot is an early-career researcher and an expert in mass spectrometry-based lipidomics. He graduated with a PhD in analytical chemistry at the University of Southampton (UK), under the supervision of Dr John Langley, specialising in supercritical fluid chromatography and mass spectrometry. His interest in lipids started while a postdoc in the team of Professor Anthony Postle, still in Southampton. A member of SLING since 2009, his research centres on separation sciences, mass spectrometry, and their applications to life sciences, especially lipid biochemistry. He has developed chromatographic and mass spectrometric methods for the identification and quantification of lipids in diverse biological systems. This has included successful local and international collaborations. Relevant Financial Disclosures (within past 24 months, reported on Mar 05, 2026) No relevant financial relationship(s) to disclose. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation NOT REQUIRED. Michael Chen, MD MSc The University of British Columbia Dr. Michael Chen is a clinical pathologist, specializing in clinical chemistry and translational mass spectrometry. He is the Department Head and Medical Director of Laboratory Medicine, Pathology and Medical Genetics at Island Health, and Provincial Discipline Lead at Provincial Health Services Authority. As a researcher, Dr Chen is the scientific director of UBC Translational Omics Lab in the Victoria General Hospital. He is also the director of Vancouver Island Biobank, and he co-chairs the BC Biobank Network. Dr. Chen’s research focuses on clinical mass spectrometry, biobanking, biomarker validation and clinical implementation. Relevant Financial Disclosures (within past 24 months, reported on Apr 18, 2026) Ownership Interest Pataigin Inc Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation NOT REQUIRED. Course Schedule Segment 1 : Monday 09:50 - 12:00 (2.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 8.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2558

Monday 1220 1420

Short Course Lunch Break @ Your Choice Your choice! This non-MSACL sponsored meal break is your chance to explore the culinary delights within the city of Montreal. MSACL recommendations. Timeout Market is a good balance of proximity, ease and quality -- and a great option if flying solo. 2785

Monday 1400 1740

Short Course Coffee Breaks @ Montreal 1-3 2783

Monday 1420 1740

LC-MSMS 203 : Validation of Quantitative LC-MS/MS Assays for Clinical and Academic Use @ Montreal 4 Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2745

Monday 1420 1740

LC-MSMS 202 : Data Driven LC-MS Troubleshooting @ Montreal 5 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2757

Monday 1420 1740

Metabolomics 203 : Metabolomics from Data Collection to Data Analysis @ Montreal 6 Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2760

Monday 1420 1740

LC-MSMS 101 : Getting Started with Quantitative LC-MSMS in the Diagnostic Laboratory @ Montreal 7-8 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2567

Monday 1420 1740

GC-MS 101 : Intro to Clinical Applications @ Westmount 1 Andrew T Nelson, MD, PhD University of Rochester Medical Center Andrew T Nelson is the Associate Director of Clinical Chemistry and an Assistant Professor in Pathology & Laboratory Medicine at the University of Rochester Medical Center. He is also a diplomate of the American Board of Pathology. Previous training included a Clinical Pathology Residency at University of Texas Southwestern Medical Center, MD from the University of Texas-Medical Branch, and PhD in Organic Chemistry from the University of Texas at Austin. Current interests include follow up on abnormal newborn screens, toxicology, and the role of lipids in human health and disease. Relevant Financial Disclosures (within past 24 months, reported on Jan 14, 2026) No relevant financial relationship(s) to disclose. Course Schedule Segment 1 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 6.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2743

Monday 1420 1740

Lipidomics 101 : Mass Spectrometry-based Lipidomics and Clinical Applications @ Westmount 2 Course Schedule Segment 1 : Monday 09:50 - 12:00 (2.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 8.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2752

Monday 1420 1740

Automation 201 : Streamlining Clinical Analysis through Efficient Workflow Integration @ Westmount 4 Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2566

Monday 1420 1740

Clinical Proteomics 202 : MS-based Precision Diagnostics by Molecular Protein Analysis @ Westmount 5 Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2748

Monday 1420 1740

Clinical Proteomics 201 : Clinical Proteomics @ Westmount 6 Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2565

Monday 1440 1800

Sample Prep 101 : Sample Preparation and Alternative Matrices for LC-MS Assays @ Outremont 1 Course Schedule Segment 1 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 2 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 3 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 4 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2724

Monday 1440 1800

Leadership 101 : Clinical MS Quality Improvement, Regulations, and Risk Management in Action @ Outremont 3 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2731

Monday 1440 1800

Data Science 100 : Data Literacy @ Outremont 4 Course Schedule Segment 1 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2564

Monday 1440 1800

Data Science 101 : Breaking Up with Excel and Rebounding with R and Claude @ Outremont 5 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2561

Monday 1440 1800

Data Science 203 : Machine Learning : A Gentle Introduction @ Outremont 6 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2563

Monday 1440 1800

Data Science 301 : Intro to Deep Learning : From Neurons to Transformers @ Outremont 7 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2735

Monday 1740 1830

Happy Half-Hour! @ Montreal 1-3 Open to all conference registrants. Use this time to finalize dinner plans with fellow attendees. 2569

Monday 1830 2100

Dinner @ Your Choice Your choice! This non-MSACL sponsored meal break is your chance to explore the culinary delights within the city of Montreal. MSACL recommendations. 2570

Monday 2100 2330

MSACL Networking Lounge @ Bisco Retaurant, Hotel Level All attendees are welcome to close out the evening in the Bisco (Hotel breakfast area). MSACL will host snacks and drinks (requires token - pick up tokens at the door or from MSACL Staff). Must be wearing your badge to attend. Drinks will be available through 11:30pm. The Lounge includes a pleasant outdoor patio along a stream and among some small trees and shrubbery, which may be enjoyable should we have nice weather. Open to all conference registrants. 2571

Tuesday

Tuesday 730 2100

Registration + Help Desk @ Foyer, Conference Level 2575

Tuesday 745 845

Industry Breakfast Workshop(s)

	Open to All Conference Registrants. Guidance for Hosts: Presentations should end at 8:35 so that short course attendees can head to their courses during Q&A.
	Bruker Scientific @ Salon Bonaventure, Hotel Level Workshop summary coming soon ...

Tuesday 745 900

Breakfast @ Montreal 1-3 Pick-up your badge on the conference level then find breakfast in the room adjacent to the reg desk (Montreal 1-3) where you can touch base with other attendees. Alternatively, pair your breakfast with a workshop, upstairs, in Salon Bonaventure. 2576

Tuesday 840 1200

LC-MSMS 203 : Validation of Quantitative LC-MS/MS Assays for Clinical and Academic Use @ Montreal 4 Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2746

Tuesday 840 1200

LC-MSMS 202 : Data Driven LC-MS Troubleshooting @ Montreal 5 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2756

Tuesday 840 1200

Metabolomics 203 : Metabolomics from Data Collection to Data Analysis @ Montreal 6 Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2560

Tuesday 840 1200

LC-MSMS 101 : Getting Started with Quantitative LC-MSMS in the Diagnostic Laboratory @ Montreal 7-8 Course Schedule Segment 1 : Sunday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 4 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 5 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2584

Tuesday 840 1200

GC-MS 101 : Intro to Clinical Applications @ Westmount 1 Course Schedule Segment 1 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 6.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2744

Tuesday 840 1200

Lipidomics 101 : Mass Spectrometry-based Lipidomics and Clinical Applications @ Westmount 2 Course Schedule Segment 1 : Monday 09:50 - 12:00 (2.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 8.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2585

Tuesday 840 1200

Automation 201 : Streamlining Clinical Analysis through Efficient Workflow Integration @ Westmount 4 Course Schedule Segment 1 : Sunday 14:20 - 17:40 (3.00 contact hrs) Segment 2 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 3 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 4 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2749

Tuesday 840 1200

Clinical Proteomics 202 : MS-based Precision Diagnostics by Molecular Protein Analysis @ Westmount 5 Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2747

Tuesday 840 1200

Clinical Proteomics 201 : Clinical Proteomics @ Westmount 6 Course Schedule Segment 1 : Monday 08:40 - 12:00 (3.00 contact hrs) Segment 2 : Monday 14:20 - 17:40 (3.00 contact hrs) Segment 3 : Tuesday 08:40 - 12:00 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2587

Tuesday 900 1230

Short Course Coffee Breaks @ Montreal 1-3 2786

Tuesday 900 1220

Sample Prep 101 : Sample Preparation and Alternative Matrices for LC-MS Assays @ Outremont 1 Course Schedule Segment 1 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 2 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 3 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 4 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 12.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2727

Tuesday 900 1220

Data Science 100 : Data Literacy @ Outremont 4 Course Schedule Segment 1 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 9.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2586

Tuesday 900 1220

Data Science 101 : Breaking Up with Excel and Rebounding with R and Claude @ Outremont 5 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2581

Tuesday 900 1220

Data Science 203 : Machine Learning : A Gentle Introduction @ Outremont 6 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2583

Tuesday 900 1220

Data Science 301 : Intro to Deep Learning : From Neurons to Transformers @ Outremont 7 Course Schedule Segment 1 : Sunday 09:00 - 12:20 (3.00 contact hrs) Segment 2 : Sunday 14:40 - 18:00 (3.00 contact hrs) Segment 3 : Monday 09:00 - 12:20 (3.00 contact hrs) Segment 4 : Monday 14:40 - 18:00 (3.00 contact hrs) Segment 5 : Tuesday 09:00 - 12:20 (3.00 contact hrs) Total Contact Hours: 15.00 (Ten-minute breaks occur after each full instructional hour when another hour follows. Breaks are excluded from contact hour calculations.) --------------- View Full Course Description 2732

Tuesday 930 1030

Industry Workshop(s)

No workshops currently booked for this time period.

Tuesday 1030 1100

Intermission @ Salon Bonaventure, Hotel Level 2787

Tuesday 1100 1200

Industry Workshop(s)

No workshops currently booked for this time period.

Tuesday 1200 1230

Intermission @ Salon Bonaventure, Hotel Level 2788

Tuesday 1230 1345

Industry Workshop(s)

	Pre-register for your session of choice to help us order lunches accordingly.
	Roche @ Montreal 4 Workshop summary coming soon ...	Shimadzu @ Montreal 5 Workshop summary coming soon ...	Thermo Fisher Scientific @ Montreal 6-8 Workshop summary coming soon ...

Tuesday 1345 1415

Place Posters - Group WEDNESDAY @ St Laurent (Exhibits) WEDNESDAY posters to be placed. 2717

Tuesday 1345 1415

Coffee Break @ Montreal 1-3 2594

Tuesday 1415 1545

Academic Workshop : LLM Coding and Vibe Coding Workshop @ Salon Bonaventure, Hotel Level Chris McCudden, Ph.D., DABCC, FACB, FCAC University of Ottawa Dr. McCudden is a Clinical Biochemist at the Ottawa Hospital in Ontario, Canada. He is a Professor and Vice Chair of the Department of Pathology & Laboratory Medicine at the University of Ottawa. He serves as the Deputy Chief Medical Scientific Officer and Medical Director of Informatics and Information Technology for the Eastern Ontario Regional Laboratory Association. He serves as Board Secretary for the Association for Diagnostics and Laboratory Medicine. Dr. McCudden's academic interests include automated chemistry, data analytics & machine learning, quality improvement, plasma cell dyscrasias, and audit and feedback for laboratory stewardship. Relevant Financial Disclosures (within past 24 months, reported on May 14, 2026) No relevant financial relationship(s) to disclose. Summary: Coding tools have progressed at warp speed, moving rapidly from syntax troubleshooting to autonomous multi-agent workflows, the potential for AI in programming is spectacular. People with experience writing programs will be curious about the capabilities of AI tools, those who don't write code will wonder if they should ever learn, and everyone will want to understand the risks and benefits. This workshop will focus on "Vibe Coding", using AI tools to rapidly develop, prototype, and iterate software. Participants will hear about and discuss the realm of the possible, explore different AI coding tools, and consider if, how, and when an AI-developed application should be developed securely, safely, and effectively. Through the workshop, the group will create a new application, tackling technical and validation challenges, while identifying and mitigating potential risks and failure modes. Syllabus: Landscape of AI tools for coding: from chatbots to multi-agent frameworks Vibe coding, who, what, when, where, why, how Failure modes, ethics, risks Guardrails, best practices, and safety From idea to implementation, vibe coding an app Objectives: Differentiate vibe coding from traditional software development Describe how AI tools can be used for coding Identify risks and benefits of using AI to write code Critically evaluate a vibe-coded application 2596

Tuesday 1415 1545

Academic Workshop : Guidance Reimagined : Making CLSI Practical for Mass Spec LDT Developers @ Montreal 4 Paula Ladwig, MS, MLS(ASCP) Mayo Clinic Paula M. Ladwig, MS, MLS(ASCP), is a Principal Developer with the Clinical Mass Spec Development Laboratory and an Assistant Professor in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, MN. She has over 15 years of experience in LC-MS LDT development and validation. Her interests include the implementation of therapeutic drug monitoring of monoclonal antibody therapeutics by LC-MS methods. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) No relevant financial relationship(s) to disclose. Michelle R. Campbell, M.S., MLS(ASCP)MB(ASCP),SC(ASCP) Mayo Clinic Relevant Financial Disclosures (within past 24 months, reported on Jan 05, 2026) No relevant financial relationship(s) to disclose. Summary Liquid-chromatography mass spectrometry (LC-MS) is utilized in many larger clinical laboratories, reference laboratories or research laboratories for developing assays for new biomarkers, for analytes for which alternative technologies lack specificity, or for high volume assays requiring greater throughput. In the life cycle of a new assay, CLSI guidance documents are used by laboratory developed test (LDT) developers to meet regulatory and accreditation requirements during the design, development, validation and implementation of LDTs into the clinical lab setting. These same documents may also be useful for researchers to use for good practice study design, clinical trials and/or publishing study results. Since these consensus-driven documents are developed to be broadly applicable, they can be challenging to navigate, may not fully address technology-specific study design considerations, use terminology and examples not common to the general laboratory and may not be specific or applicable to LC-MS. In response, CLSI has undertaken a strategic re-envisioning of the Method Evaluation (formerly referred to as Evaluation Protocol) category of documents. This workshop will showcase improvements that CLSI is implementing to improve the experience for those who utilize their documents. The presenters will provide before-and-after examples, in an interactive format with the audience, to demonstrate how CLSI can better support those who work with LC-MS technology. Finally, the workshop will also consist of interactive brainstorming between the presenters and audience on topics such as gaps seen with current CLSI documents and how researchers and LDT developers who utilize LC-MS may take advantage of the new CLSI model to propose new targeted or niche-scoped guidance, examples, and tools. Syllabus Short overview of CLSI with a focus on guidance documents and tools specific for Method Evaluation and LC-MS technology. Exploration of the updated Method Navigator tool to showcase its utility as a resource to find CLSI guidance to support regulatory and accreditation requirements throughout the Test Life Phases Model. Introduction to a new framework for CLSI Method Evaluation guidelines designed to provide more concise, phase- and technology-specific guidance using examples for linearity and method comparison studies. Review of recently published Method Evaluation documents of interest to LC-MS researchers and LDT developers. Open discussion on applying CLSI guidance in practice and identifying opportunities for improvement to CLSI’s current Method Evaluation portfolio. Objectives Describe recent improvements in CLSI Method Evaluation documents and tools that support LC-MS users to include both researchers and developers of LDTs. Compare historical CLSI guidance approaches with the new, targeted strategies. Use the CLSI Method Navigator tool to identify guidance documents relevant to each phase of the laboratory test life cycle. Identify gaps in current guidance and discuss opportunities to enhance CLSI guidance for LC-MS technology. Develop targeted study designs for LC-MS using the updated CLSI framework. 2601

Tuesday 1415 1545

Academic Workshop : Design of Experiments for Optimizing LC MS Clinical Assays : Principles and Case Studies @ Montreal 5 Margret Thorsteinsdottir, PhD University of Iceland Professor in Pharmaceutical Analytical Chemistry at the Faculty of Pharmaceutical Sciences, University of Iceland and R&D Director of ArcticMass LTd, Reykjavik, Iceland. Dr. Thorsteinsdóttir received her PhD from Uppsala University, Sweden in 1998. From 2000 to 2009 she was the managing director of Bioanalytical Laboratories at deCODE Genetics, Reykjavik, Iceland. She has extensive experience in development of analytical methods for metabolite profiling and quantification of clinical biomarkers in various biofluids utilizing chemometrics with the goal of improved clinical management of patients towards personalized patient care. Her current research interest includes studies of lipid metabolism in cancer cells and profiling plasma derived biomarkers for early detection of BRCA-related breast cancer. She is responsible for implementation of clinical mass spectrometry for support of diagnostics and therapeutic drug monitoring in collaboration with ArcticMass and the Landspitali University Hospital, Reykjavik, Iceland with major focus on quantitative targeted proteomics for clinical diagnosis. She is a principal investigator of the Icelandic Research Rannis projects, profiling metabolites for breast cancer diagnosis and search for novel biomarkers for early breast cancer diagnosis by metabolomics. Dr. Thorsteinsdóttir is a principal investigator for the Marine Biotechnology ERA-net project CYNOBESITY and the Horizon 2020 project MossTech, with the main task to isolate, identify and structurally characterize bioactive compounds from cyanobacteria, Icelandic mosses and liverworts. She is one of the founders of Females in Mass Spectrometry (FeMS), she is a vice-leader of the working group clinical significance and applications of (epi)lipidomics in the pan-European network, EpiLipidNET and vice-chair of the Nordic Metabolomics Society. Relevant Financial Disclosures (within past 24 months, reported on Mar 12, 2025) No relevant financial relationship(s) to disclose. Finnur Freyr Eiriksson, PhD University of Iceland / ArcticMass Relevant Financial Disclosures (within past 24 months, reported on Mar 04, 2026) No relevant financial relationship(s) to disclose. Mark Kushnir, PhD ARUP Institute for Clinical & Experimental Pathology Mark Kushnir is Scientific Director of Mass Spectrometry R&D at ARUP Institute for Clinical and Experimental Pathology and Adjunct Professor at the Department of Pathology, University of Utah School of Medicine. Mark received PhD in Analytical Chemistry from Uppsala University (Uppsala, Sweden); his main areas of interest include development, application and clinical evaluation of novel mass spectrometry based clinical diagnostic methods for small molecule, protein and peptide biomarkers. He is author/coauthor of over 110 scientific peer reviewed publications. Relevant Financial Disclosures (within past 24 months, reported on Apr 13, 2026) Salary ARUP Laboratories Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Using Generic Terms? NO Conflict mitigation NOT REQUIRED. Summary Design of experiments (DoE) is an efficient strategy for developing and optimizing LC-MS/MS methods used to quantify biomarkers in complex biological matrices. Because LC‑MS/MS workflows involve multiple interdependent processes and numerous experimental variables, DoE provides a structured and efficient framework for identifying influential factors, modelling system behavior, and achieving maximum analytical performance with minimal experimental effort. This workshop will introduce the fundamental principles of DoE with a strong focus on practical implementation. Participants will be guided through the three main stages of a DoE‑driven method development strategy: factor screening, response optimization, and robustness assessment. To demonstrate the value of DoE compared with traditional one‑factor‑at‑a‑time approaches, two applied case studies will be presented. The first case study focuses on optimizing sample preparation in a bottom-up targeted protein LC-MS workflow. The second demonstrates DoE based optimization of a UPLC-MS/MS assay for clinical diagnostic and therapeutic drug monitoring in patients with adenine phosphoribosyltransferase (APRT) deficiency. In both studies, polynomial models were constructed, central composite designs were used to evaluate significant factors, and partial least squares (PLS) regression was applied to relate variables to analytical responses. These studies demonstrate how DoE can reduce sample preparation time and enable efficient optimization of biomarker quantification, including urinary 2,8‑dihydroxyadenine (DHA) and adenine. Finally, a demonstration of DoE‑based robustness testing, showing how intentional variation of key parameters can reveal critical factors and interactions that influence method performance. Attendees will gain practical insight into applying DoE to assessing method reliability and supporting long‑term method robustness. Syllabus Design of Experiments (DoE) – Get it right from the beginning Basic concept and assessment of DoE Optimization of sample preparation and LC-MS/MS clinical assay by DoE Evaluation of robustness of an analytical method by DoE Objectives Explain basic principles and concepts of experimental design. Discuss different types of experimental designs. Discuss interpretation of the results and implications of the findings. Provide examples of experimental design application in the process of method development and evaluation. 2595

Tuesday 1415 1545

Academic Workshop : Quantification of Protein and Peptide Biomarkers in Diabetes Clinical Research: An Update @ Montreal 6-8 Salvatore Sechi, PhD NIDDK/NIH DR. Sechi is the program director for proteomics and systems biology at the NIDDK/NIH. His responsibilities include the oversight of a research program on the application of structural biology and proteomics to diabetes, endocrinology, and metabolic diseases. The structural biology component comprises studies that are aimed at characterizing the 3-dimensional structure and function of proteins, and studies related to folding, stability, and novel structure design. The proteomic component focuses on characterizing the proteome or subset of the proteome, with the main goal of furthering our understanding of disease etiology and pathophysiology. For this purpose, researchers within this program often aim to identify protein biomarkers and examine signal transduction pathways and networks. Typically, large-scale approaches such as protein arrays or mass spectrometry are applied within these types of projects. The samples used can include biofluids or biopsies from human specimens as well as animal and cell models. The portfolio also involves computational and bioinformatic studies that address proteomic issues as they relate to diseases of interest to the NIDDK. The systems biology program that Dr. Sechi manages comprises research projects that study how the higher-level properties of complex biological systems arise from the interactions among their parts. Within this new discipline, researchers often use high-throughput technologies (e.g., genomics, proteomics, epigenomics, and metabolomics) and integrate the resulting data sets to develop models of complex biological systems. Within this program, researchers aim to characterize molecular pathways that lead to diabetes and develop predictive models. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds GE HealthCare Technologies, Merck, Organon, Pfizer, Viatris Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Andy Hoofnagle, MD, PhD University of Washington Dr. Hoofnagle's laboratory focuses on the precise quantification of recognized protein biomarkers in human plasma using LC-MRM/MS. In addition, they have worked to develop novel assays for the quantification of small molecules in clinical and research settings. His laboratory also studies the role that the systemic inflammation plays in the pathophysiology of obesity, diabetes, and cardiovascular disease. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Grant/Research Support Waters, Inc. Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation IN PROCESS. Wei-Jun Qian, PhD PNNL Dr. Wei-Jun Qian is a bioanalytical chemist whose research centers primarily on the development and applications of mass spectrometry-based approaches for better quantify the dynamic changes in protein abundances and protein post-translational modifications in biological and clinical applications. Dr. Qian is currently a Staff Scientist at the Integrative Omics group in the Biological Sciences Division at PNNL, where he has worked since 2002. Dr. Qian has received several prestigious honors, including a National Institutes of Health Director’s New Innovator Award (2009), and a Presidential Early Career Award for Scientists and Engineers (PECASE) in 2011. His current research involves the development of chemical proteomic approaches for site-specific quantification of cysteine-based redox modifications and more sensitive selected reaction monitoring (SRM)-based targeted quantification techniques with applications in pancreatic islets, diabetes, and oxidative stress-related disease areas. In addition to research, Dr. Qian is actively involved in training and mentoring postdoctoral researchers and intern students. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) No relevant financial relationship(s) to disclose. Jun Qu, PhD SUNY,Pharmaceutical Sciences Department Jun Qu is a professor in the Department of Pharmaceutical Sciences of SUNY-Buffalo, and the director of Proteomics and Pharmaceutical Analysis Group in NY Center of Excellence in Life Sciences. His research focus is the development of protein bioanalysis strategies, both on global and targeted level, for quantitative investigation of pharmaceutical/clinical systems. Qu lab is also one of the leaders in LC-MS-based characterization of protein drugs and their targets in pre-clinical models. Relevant Financial Disclosures (within past 24 months, reported on Jul 17, 2025) No relevant financial relationship(s) to disclose. Michael MacCoss, PhD University of Washington The focus of the MacCoss laboratory is in the development and application of cutting-edge mass spectrometry-based technologies for the analysis of complex protein mixtures. Dr. MacCoss’ primary area of expertise is in protein biochemistry, nanoflow liquid chromatography, mass spectrometry instrumentation, and computational analysis of mass spectrometry data. He has ~30 years of mass spectrometry experience that bridges the fields of protein mass spectrometry, isotope ratio mass spectrometry, and quantitative mass spectrometry. The MacCoss laboratory has been actively applying these tools to important areas of biology including but not limited to, the basic biology of aging, neurodegenerative disease, protein-protein interactions, insulin signaling, cancer, measurement of protein half-life, transcriptional regulation, characterization of post-translational modifications, proteogenomics, and clinical diagnostics. The MacCoss laboratory is widely known for its expertise in the development and support of proteomics software tools. This expertise in mass spectrometry and the support of open-source software tools will be critical to the success of this project. Dr. MacCoss has been actively involved in the scientific direction and management of NIH centers, program projects, consortia, and large quantitative proteomics data production efforts since he arrived at UW in 2004. The MacCoss lab has worked on proteomics application of the biology of aging for the last 20 years and has been working in the analysis of samples of relevance to Alzheimer’s disease for the last decade. The MacCoss lab has trained 15 Ph.D. students and 15 postdoctoral fellows. There have been 1000s of individuals who have attended the Quantitative Proteomics Courses co-taught by MacCoss lab personnel. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Consultant Fees ThermoFisher Scientific, Alnylam Grant/Research Support Agilent, Bruker, Sciex, Shimadzu, ThermoFisher, Waters Committee/Board/Advisory Board Talus Biosciences, Profound Therapeutics Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Summary Diabetes represents a collection of endocrine disorders with severe systemic complications, including type 1 diabetes, an autoimmune condition characterized by insulin deficiency. The disease pathogenesis, trajectory, and end-organ damage are variable from patient to patient. As a result, the precise and accurate quantification of proteins and peptides involved in diabetes will help facilitate research into disease pathogenesis and ultimately improve the diagnosis, prognosis, and therapeutic management of patients with diabetes. Unfortunately, most of the studies to date have relied on immunoassays, with little effort put into demonstrating the specificity of the reagents or the robustness of the assays. Furthermore, recent publications have highlighted the limitations of many commercial assays, including a failure to detect the intended target. Rigor and reproducibility could be substantially improved by applying mass spectrometry to the quantification of these biomarkers. Major improvements in sample preparation and instrumentation have made mass spectrometry–based targeted proteomics a highly reproducible methodology for detecting and quantifying proteins and peptides. In addition, the ability to quantify specific proteoforms provides insight into prohormone processing and post-translational modifications and creates an opportunity to identify and validate new biomarkers that can be used for disease stratification. The NIDDK continues to fund several projects that aim to use targeted mass spectrometry to quantify human plasma/serum proteins and peptides of interest to the diabetes clinical research community. During this workshop, the presenters will provide an update on their recent progress toward this goal that have been made by the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium, with a special focus on biomarkers important in type 1 diabetes. Syllabus Detecting proteins and peptides in human serum and plasma Preparing samples for targeted proteomic analysis The role of antibodies and immunoprecipitation in LC-MS quantification of protein and peptide biomarkers Examples of assays that can be translated to clinical research or clinical care Objectives Outline the potential utility of biomarkers in clinical research and clinical care in diabetes Provide the rationale for the use of LC-MS/MS methods in the quantification of peptide and protein biomarkers, including proteoform-specific biomarkers List the advances in sample preparation and instrumentation that enable the development of assays to peptide and protein biomarkers in human serum/plasma Identify the hurdles that exist for the development of novel protein and peptide biomarker assays Demonstrate the reproducibility and robustness of LC-MS assays through inter-lab assessments. 2600

Tuesday 1545 1615

Buddy Program Meet-Up @ Salon Bonaventure, Hotel Level If you have not already connected, meet your Buddy during this coffee break in this dedicated area where you you can take in a view of the outdoor water, tree and duck features. Spend a short time connecting and getting oriented before continuing onto the plenary session. 2607

Tuesday 1545 1615

Coffee Break @ Montreal 1-3 2602

Tuesday 1615 1640

Welcome and Scientific Orientation @ Montreal 4-8 What you need to know for this week from the Conference Chair. Plus a JMSACL Update from the Co-Editors-in-Chief. 2603

Tuesday 1640 1730

Michael S Bereman Award Plenary Lecture @ Montreal 4-8 Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Dr. Stefani Thomas is an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota, and the Associate Medical Director of the M Health Fairview University of Minnesota Medical Center West Bank Laboratory. She earned a BA in Biological Sciences from Dartmouth College, a PhD in Pharmaceutical Sciences from the University of Southern California, and she completed a Clinical Chemistry postdoctoral fellowship at Johns Hopkins. Her research program at the University of Minnesota utilizes mass spectrometry-based clinical proteomics for therapeutic and diagnostic biomarker development. Relevant Financial Disclosures (within past 24 months, reported on Mar 03, 2024) Not yet reported. 2604

Tuesday 1730 2000

Opening Exhibits Dinner Reception @ St Laurent (Exhibits) 2606

Tuesday 1900 1950

Booth Tours @ St Laurent (Exhibits) Early Career and first time attendees are encouraged to meet at the MSACL registration desk at 5 minutes prior to start time to join a tour of the vendor booths with a guiding mentor. Booth Tour Overview 2608

Tuesday 2000 2100

Distinguished Contribution Award Plenary Lecture @ Montreal 4-8 Andy Hoofnagle, MD, PhD University of Washington Dr. Hoofnagle's laboratory focuses on the precise quantification of recognized protein biomarkers in human plasma using LC-MRM/MS. In addition, they have worked to develop novel assays for the quantification of small molecules in clinical and research settings. His laboratory also studies the role that the systemic inflammation plays in the pathophysiology of obesity, diabetes, and cardiovascular disease. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Grant/Research Support Waters, Inc. Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation IN PROCESS. On the award. 2605

Tuesday 2100 2330

MSACL Networking Lounge @ Salon Bonaventure, Hotel Level All attendees are welcome to close out the evening in Salon Bonaventure. MSACL will host snacks and drinks (requires token - pick up tokens at the door or from MSACL Staff). Must be wearing your badge to attend. Drinks will be available through 11:30pm. The Lounge includes a pleasant outdoor patio along a stream and among some small trees and shrubbery, which may be enjoyable should we have nice weather. Open to all conference registrants. 2609

Wednesday

Wednesday 730 1815

Registration + Help Desk @ Foyer, Conference Level 2610

Wednesday 800 900

Industry Workshop(s)

	Pre-register for your session of choice to help us order breakfasts accordingly.
	Waters Corporation @ Montreal 4 Workshop summary coming soon ...	Thermo Fisher Scientific @ Montreal 5 Workshop summary coming soon ...	Indigo BioAutomation @ Montreal 6-8 Workshop summary coming soon ...	Agilent Technologies @ Salon Bonaventure, Hotel Level Workshop summary coming soon ...

Wednesday 900 1700

Exhibit Hall Open @ St Laurent (Exhibits) 2617

Wednesday 915 1030

Poster Session #1 - Wed Odd @ St Laurent (Exhibits) All Wednesday Odd-numbered posters will be attended during this poster session (#1). 2623

Wednesday 930 1020

Poster Tour #1 @ St Laurent (Exhibits) Early Career and first time attendees are encouraged to meet at the MSACL registration desk at 9:25am to join a POSTER TOUR with a guiding mentor. Poster Tour Overview 2624

Wednesday 1030 1130

Plenary Lecture @ Montreal 4-8 2625

Wednesday 1130 1245

Lunch & Exhibits @ St Laurent (Exhibits) Buffet Lunch hosted by MSACL. Alternatively, attend an exhibitor lunch workshop. 2626

Wednesday 1130 1245

Industry Workshop(s)

	Host Guidance: Host presentations should not run past 12:40 so attendees have time to get to the next activity starting at 12:45.
	SCIEX @ Montreal 1-3 Workshop summary coming soon ...

Wednesday 1130 1245

Industry Petite Suite Focus Hours @ Outremont 7 Pick up lunch in the exhibit hall before grabbing a petite suite seat. Host Guidance: Plan for a 45-minute speaker from 11:45-12:30. 2707

Scientific Session 1

	Montreal 4 Keynote : Spatialomics	Montreal 5 Longitudinal Metabolomics	Montreal 6 Proteomics - Multiple Myeloma	Montreal 7-8 Endocrinology	Salon Bonaventure, Hotel Level Practical Training
1245 1305	Next Generation MALDI Imaging: FluoMALDI, RaMALDI & QMALDI Kristine Glunde The Johns Hopkins University School of Medicine Keynote Speaker	Lipidomes Over Time: Individuality, Sex Differences, and Network Dynamics in a Longitudinal Adult Cohort of Lausanne Nicolas Goss University of Lausanne	Cross-Population Validation of LC–MS Glycoprotein Biomarker Panels for High-Sensitivity Detection of Early-Stage Ovarian Cancer Michelle Hill ProSeek Bio Pty Ltd	Enzymatic Hydrolysis Strategies for Extended Steroidomic Analysis in Urine: Comparative Evaluation from Controlled Optimization to Real Sample Application Federico Ponzetto University of Turin	Pursuing Perfect Precision? Why Sample Prep Matters Matthew Crawford, Meghan Bradley
1305 1325	... Keynote, continued ...	Longitudinal Clinical Metabolomic Characterization of Systemic Stress Induced by Extreme Exercise Using LC–MS/MS and ¹H NMR Caroline Le Goff CHU Liege	Evaluation of Blood-Based Clonotypic Peptide Mass Spectrometry (M-inSight) for M-Protein Monitoring of Multiple Myeloma Sung-Eun Cho GCLabs ESAC	QconCAT Proteomics of Human Adrenals for Absolute Quantitation of Cytochrome P450 Enzymes Heather Hartmann Vanderbilt University	... Extended Talk ...
1325 1345	Spatial Multi Omics Reveals Modulation of the Tumor Microenvironment in Ovarian Cancer Erin Seeley The University of Texas MD Anderson Cancer Center	Serum Metabolic Signatures of Cognitive Resilience in a Longitudinal Aging Cohort Anthony Molina UCSD Keynote Speaker	The Study of Serum Monoclonal Protein (M-Protein) Glycosylation Patterns for Risk Stratification in Multiple Myeloma Priscilla Yeung Stanford/UCSF	Environmental Pollutants and Adrenal Steroidogenesis Mark Kushnir ARUP Institute for Clinical & Experimental Pathology	... Extended Talk ...

Wednesday 1345 1500

Poster Session #2 - Wed Even @ St Laurent (Exhibits) All Wednesday Even-numbered posters will be attended during this poster session (#2). 2627

Scientific Session 2

	Montreal 4 Keynote : Microbiology	Montreal 5 Automation in Clinical MS	Montreal 6 Metabolomic Profiling	Montreal 7-8 Proteomics - CVD	Salon Bonaventure, Hotel Level Practical Training
1500 1520	Decoding Microbial Messages: Untargeted Metabolomics and Data Science-Driven Discovery Ipsita Mohanty Penn State University Keynote Speaker	From Complexity to Efficiency: Transforming LC-MS/MS Tests Through Strategic Redevelopment Yubo Chai Mayo Clinic	A Novel Tribrid LC-MS Workflow for Concurrent Quantification and Untargeted Profiling in Human Plasma for Evaluating Kidney Transplant Outcomes Antonis Myridakis Imperial College London, United Kingdom	Decentralized Risk Assessment for Sudden Cardiac Arrest: Cross-Matrix Transferability of Plasma Proteomic Signatures to Remote Blood Microsampling Jennifer van Eyk Cedars-Sinai Heart Institute	Dude, Where’s my Peak? Best Practices for Optimizing and Troubleshooting Chromatography Peter Wegwerth, Alison Lightfoot, Chris Thompson
1520 1540	Imaging with Mass Spectrometry: Spatial Metabolomics to Study Intestinal Inflammation Boone Prentice University of Florida Keynote Speaker	A Structured Productivity Challenge Study of a Fully Automated Mass Spectrometry System Katharina Habler LMU University Hospital, LMU Munich	Clinical Utility of the Intelligent Knife Sampling Device for Intraoperative Margin Assessment: A Prospective Case Series of 66 Breast Cancer Surgeries Martin Kaufmann Queen’s University	Optimization of Nano-LC–MRM-MS Enables High-Throughput Quantitative Serum Proteomics in Large Cardiovascular Disease Cohort Kári Arnarson University of Iceland	... Extended Talk ...
1540 1600	... Keynote, continued ...	Clinical Implementation of the Roche Cobas I 601 at Scale Russell Grant Labcorp	Clinically Adapted Rapid Evaporative Ionization Mass Spectrometry for Ex Vivo Tumor–Healthy Tissue Discrimination in Head and Neck Cancer Gabriel Stefan Horkovics-Kováts University of Regensburg	Enhanced Targeted Proteomics and Machine Learning Enable Accurate Blood-Based Detection of Hypertrophic Cardiomyopathy Jessica Fontes Guilford Street Laboratories	... Extended Talk ...

Wednesday 1600 1700

Exhibits & Happy Hour @ St Laurent (Exhibits) 2639

Wednesday 1600 1630

Remove WEDNESDAY Posters @ St Laurent (Exhibits) WEDNESDAY posters to be removed. 2715

Wednesday 1630 1700

Place THURSDAY Posters @ St Laurent (Exhibits) THURSDAY posters to be placed. 2716

Wednesday 1700 1830

Discussion Group : Career Exploration in Clinical Mass Spectrometry @ Salon Bonaventure, Hotel Level Matthew Crawford Labcorp Matthew Crawford is a Scientist II working in research and development at Labcorp in Burlington, North Carolina. He received his B.S. in Biochemistry from California State University, Northridge and is currently working towards his Ph.D. in Analytical Chemistry from University of Texas at Arlington under the instruction of Professor Kevin Schug. At Labcorp, his focus is high-throughput method development and validation for small molecule biomarkers using LC-MS/MS and GC-MS. He’s been on the MSACL steering committee for 2024 and 2025 conferences where he’s head of the small molecule scientific committee. Relevant Financial Disclosures (within past 24 months, reported on Apr 23, 2026) Honorarium/Expenses MSACL Stock/Bonds Labcorp Salary Labcorp Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Discover clinical mass spectrometry career paths. This networking event is geared to early career attendees, but open to all. Get insights through informative, brief presentations on various job profiles within clinical mass spectrometry. Experts and seasoned professionals will guide you through diverse roles, making it easier to envision your own journey in this exciting industry. In addition to short panelist presentations, the event promises a delightful networking experience. Unwind and engage with fellow attendees, experts, and potential employers to expand your professional connections. Enjoy selections of refreshments; creating a relaxed environment for further discussion and relationship-building. This networking event is the perfect opportunity to continue conversations, ask questions, and make lasting connections. Employers This is your chance to connect with talent. We invite you to advertise your job postings at the event and interact with potential candidates who are passionate about clinical mass spectrometry. Share your opportunities and meet prospective candidates who are eager to contribute to your organization's success. MSACL is offering the opportunity for you to be recognized by the event chair at no charge (RSVP required) to facilitate your discussion of career opportunities with interested parties in attendance. If you are interested in representing your organization/company/lab at this event, please register your interest here. This event is formatted as a social mixer to facilitate active networking throughout the event. For representatives and hiring managers: -> There will be no booths. -> Please bring business cards or QR codes describing positions to share with attendees or place on the job board. -> You may also advertise employment opportunities on a job board. Each open position is limited to an 8.5 x 11 inch poster. Don’t miss this unique opportunity to blend career exploration, networking, and relaxation. 2643

Wednesday 1700 1830

Discussion Group : Troubleshooting Cases @ Montreal 4 View Troubleshooting Case Summaries Moderated by: Deborah French, PhD, DABCC (CC, TC), FADLM UCSF Deborah French Ph.D., DABCC (CC, TC), FADLM is a Director of Chemistry and the Director of Mass Spectrometry at the University of California San Francisco Health Clinical Laboratories. Her work currently focuses on the development and validation of LC-MS/MS assays for small molecules, specifically therapeutic drug monitoring, steroid hormones and toxicology. Deborah received her Ph.D. in biochemistry from the University of Strathclyde in Glasgow, Scotland and then completed a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, TN. She subsequently completed a ComACC Clinical Chemistry postdoctoral fellowship under the direction of Dr Alan Wu at the University of California San Francisco and is now board certified in Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Consultant Fees ARK Diagnostics, Roche Diagnostics (ended) Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Grace van der Gugten, B.Sc. Chemistry Provincial Health Services Authority, BCCDC Toxicology Lab Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Mass Spectrometry Lab Scientist in the Toxicology Lab at the BCCDC in Vancouver, BC. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!). Relevant Financial Disclosures (within past 24 months, reported on Mar 05, 2026) No relevant financial relationship(s) to disclose. Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. After fellowship, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. Next, she briefly served as a Lab Director for a small reference laboratory in PIttsburgh, PA. She then joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation. Relevant Financial Disclosures (within past 24 months, reported on Mar 08, 2026) No relevant financial relationship(s) to disclose. Joshua Hayden, PhD, DABCC, FACB Cleveland Clinic Joshua is currently the Section Head of Clinical Biochemistry at Cleveland Clinic. He earned his PhD in chemistry from Carnegie Mellon University. He conducted postdoctoral research at Massachusetts Institute of Technology before completing a two-year clinical chemistry fellowship at University of Washington and 4 years as Assistant Professor at Weill Medical College. Joshua has special expertise developing and overseeing mass spectrometry assays in the clinical laboratory. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Honorarium/Expenses Thermo (speaker) Committee/Board/Advisory Board BioPorto (ended) Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. 2789

Wednesday 1700 1830

Discussion Group : Open @ Montreal 5 2641

Wednesday 1700 1830

Discussion Group : Closing the Discovery Gap: Clinical Mass Spectrometry in Africa @ Montreal 6 Aletta Millen, PhD, MBA University of the Witwatersrand Aletta Millen is Director of the Integrated Molecular Physiology Research Initiative (IMPRI) and Assistant Dean in the Faculty of Health Sciences at the University of the Witwatersrand. Her research focuses on the role of inflammation in the development of non-communicable diseases, particularly cardiovascular and neurological disorders, with a strong emphasis on translational science and clinical relevance. A key milestone in her career has been expanding regional capacity for advanced molecular research through the development and application of novel metabolomic and mass spectrometry-based techniques. Her work has strengthened infrastructure and technical skills in the field while advancing the development of affordable, accessible screening tools for low-resource settings to support early disease detection and reduce healthcare inequities. Aletta holds an MBA from the University of the Witwatersrand and is committed to strategic academic leadership, research capacity development, and building collaborative partnerships across sectors. Relevant Financial Disclosures (within past 24 months, reported on Feb 05, 2026) No relevant financial relationship(s) to disclose. Africa bears a substantial proportion of the global burden of both infectious and non-communicable diseases, yet remains markedly underrepresented in clinically driven molecular discovery and translation. While mass spectrometry–based approaches are increasingly integrated into diagnostic development, biomarker discovery, and translational research pipelines across the Global North, the infrastructure, expertise, and sustained investment required to deploy these technologies within clinical and healthcare settings remain limited across much of the African continent. This gap has important consequences. Many of the most pressing African health challenges including cardiometabolic disorders, infectious diseases, cancers, and inflammatory conditions would benefit from molecularly informed approaches that improve disease understanding, patient stratification, and therapeutic development. However, limited local capacity for advanced mass spectrometry–based research and clinical translation means that African patient populations, disease phenotypes, and biological samples are rarely investigated using these technologies. As a result, the molecular knowledge that underpins diagnostics and therapeutic development is often generated elsewhere, creating a persistent disconnect between disease burden and discovery. This discussion session provides an opportunity to examine the unique challenges and opportunities for translating mass spectrometry–based technologies into clinical and healthcare contexts in Africa. By convening researchers from established international centres alongside emerging African initiatives, the session aims to explore how clinical mass spectrometry can be developed in resource-constrained environments, what infrastructure and training models are needed to build sustainable local capacity, and how equitable partnerships can support meaningful clinical impact. Addressing these questions is essential if advances in mass spectrometry are to contribute meaningfully to global health rather than reinforce existing inequities in biomedical discovery and translation. 2777

Wednesday 1700 1830

Discussion Group : If the Result Is a Score, What Does Accuracy Mean? Validating Multi-Marker Panels in Clinical MS @ Montreal 7-8 Michelle Hill, PhD, BSc (Hon I), BA ProSeek Bio Pty Ltd Michelle Hill, PhD is a biomedical scientist and entrepreneur specializing in clinical proteomics and glycoprotein biomarker translation. She is Founder and CEO of Proseek Bio, developing LC–MS-based clinical blood tests, starting with ovarian cancer presurgical triage. She has authored over 140 publications and is an inventor on multiple diagnostics patents. Michelle previously held research leadership roles, and served as Secretary General of the Human Proteome Organization (HUPO). Relevant Financial Disclosures (within past 24 months, reported on Apr 20, 2026) Salary Proseek Bio Pty Ltd Ownership Interest Proseek Bio Pty Ltd Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Using Generic Terms? YES Conflict mitigation NOT REQUIRED. Summary Clinical mass spectrometry has historically focused on absolute quantification of single analytes, with well-established conventions around calibration, QC, and regulatory expectations. However, clinical innovation is moving toward multi-marker panels and composite score outputs that incorporate algorithmic interpretation. This is already occurring in the research and translational literature for LC-MS-based proteomic panels, where multiple proteins are combined into predictive models or classifier outputs for disease detection, triage, or risk stratification. While these approaches show promise, they challenge the field because the final clinical result is not a concentration but a probability score or classification. This shift raises important questions on the validation metrics for clinical mass spectrometry-based multivariate index assays: What does analytical validation look like for a score without external calibration and absolute quantification? What are the appropriate QC metrics? How do labs demonstrate traceability, reproducibility, and medical decision limits? At what point does validation move beyond metrology toward clinical calibration? By comparing traditional targeted assays with emerging score-based LC-MS panels, this roundtable aims to identify best practices and highlight gaps in current clinical, regulatory, and quality frameworks for translating these novel assays. The session is intended as a neutral, field-level discussion of translational challenges as the community navigates this next frontier of clinical mass spectrometry, not promotion of any specific product. 2768

Wednesday 1700 1830

Industry Petite Suite Focus Hours @ Outremont 7 2709

Wednesday 1830 2100

FREE Evening @ Your Choice Your choice! Dinner is off-site on your own. This non-MSACL sponsored meal break is your chance to explore the culinary delights within the city of Montreal. MSACL recommendations. 2644

Wednesday 2100 2330

MSACL Networking Lounge @ Salon Bonaventure, Hotel Level All attendees are welcome to close out the evening in Salon Bonaventure. MSACL will host snacks and drinks (requires token - pick up tokens at the door or from MSACL Staff). Must be wearing your badge to attend. Drinks will be available through 11:30pm. The Lounge includes a pleasant outdoor patio along a stream and among trees and shrubbery, which may be enjoyable should we have nice weather. Open to all conference registrants. 2645

Thursday

Thursday 730 1730

Registration + Help Desk @ Foyer, Conference Level 2648

Thursday 730 800

Discussion Group Breakfast Service @ Montreal 1-3 Breakfast buffet is available for attendees participating in Discussion Sessions, including Industry Petite Suite Discussions and Academic Discussions. Prepare your breakfast plate in Montreal 1-3 and and proceed to your selected discussion breakout room, which begins promptly at 7:45 AM. Seating in all discussion rooms is first come, first served. If you are not attending a Discussion Session, breakfast is available for purchase on the hotel level at Le Bisco. 2652

Thursday 745 845

Industry Breakfast Workshop @ Montreal 1-3 2710

Thursday 745 845

Industry Petite Suite Focus Hours @ Westmount 1 Host Guidance: Attendees will pick up breakfast in Montreal 1-3. 2764

Thursday 745 845

Discussion Group : Decoding the Mobility Dimension: Advanced Data Analysis for Clinical Ion Mobility–MS Applications @ Westmount 6 Christopher Chouinard, PhD Clemson University I received my PhD from University of Florida in 2016, where I developed ion mobility-mass spectrometry (IM-MS) methods for steroids and vitamin D metabolites. I then worked as a post-doctoral research at Pacific Northwest National Laboratory, building Structures for Loss Ion Manipulations (SLIM) ion mobility instrumentation for application in metabolomics and proteomics. In 2018, I began my independent career as an Assistant Professor at Florida Institute of Technology. I have since moved to Clemson University in August 2022. Work in my research group focuses on ion mobility-mass spectrometry (IM-MS)-based methods and technology, including structurally selective reactions for improved characterization of steroids and other controlled substances. Relevant Financial Disclosures (within past 24 months, reported on Apr 22, 2026) Grant/Research Support MOBILion Systems Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. All relevant financial relationships have been MITIGATED. Robin Kemperman, PhD Children’s Hospital of Philadelphia Robin Kemperman received his Bachelor's in chemistry from the HAN University of Applied Sciences in The Netherlands. Thereafter, he fulfilled his MSc and PhD in analytical chemistry at the University of Florida under the direction of Dr. Richard Yost. Currently, he works at the Children's Hospital of Philadelphia as Sr. Mass Spectrometrist in the Metabolic and Advanced Diagnostics Lab. Dr. Kemperman's work has covered a variety of aspects in mass spectrometry, including targeted analysis of steroids and ketone bodies using LC-MS/MS, bile acid, opioid, and glycan isomer separations using ion mobility spectrometry, and metabolomics High-Resolution MS. Dr. Kemperman is experienced in clinical MS-based validations and has presented his work at a variety of national and international meetings. Focusing on the future, he is interested in working on novel innovations for biomedical and clinical applications. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Consultant Fees LGC Group Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Summary: Ion mobility-mass spectrometry (IM-MS) is now a ubiquitous technique in biomedical research, with nearly all major MS vendors offering one or more commercially-available IM options. Nevertheless, its transition into the “prime-time” of clinical analysis has been slowed by numerous challenges, not the least of which being difficult/cumbersome data analysis. In this workshop, we will briefly introduce the various IM techniques and their deliverables, ranging from drift/arrival time to mobility (K) and collision cross section (CCS). We will then focus on real datasets (applicable to the clinical lab) and discuss how/where ion mobility can be beneficial. Finally, we will present several “open-source” IM data processing software options and also how these and other tools could be integrated into a clinical lab data processing workflow. Syllabus Basic introduction to different IMS techniques Discussion of deliverables from the IMS techniques: how they are measured/validated, what they reveal about chemistry/structure, and how they support separations Demonstration of data‑processing tools for IM‑MS datasets Objectives Understand the basic operating principles of IMS and the differences between the different techniques (e.g., drift tube, traveling wave, FAIMS/DMS, etc.) Understand the deliverables of the various techniques (drift/arrival time, compensation voltage, mobility, collision cross section, etc.) Understand the basics of an ion mobility data analysis workflow, how it can be applied to different data sets, and the benefits of incorporating IM into existing LC‑MS experiments 2642

Thursday 745 845

Discussion Group : Patient Centric Remote Sampling for Clinical Diagnostics – A 2026 Regulatory Update @ Outremont 1 Russell Grant, PhD Labcorp Dr. Grant earned a first-class honors degree in Industrial Chemistry from Cardiff University and a PhD in Chromatographic and Mass Spectrometric technologies from the University of Swansea, Wales, United Kingdom. He continued his scientific training in various industrial settings, which have included senior scientist at GSK, Principal scientist at Cohesive Technologies, Technical director at Eli Lilly, and Director of Mass Spectrometry at Esoterix Endocrinology. Dr Grant is currently the Vice President of Research and Development and co-discipline director for Mass spectrometry at Labcorp. Dr Grant has pioneered the use of direct injection technologies, chromatographic systems multiplexing, microsampling, utility of automation, and other new analytical platforms in direct patient care. His research goals are focused upon improvements in speed, sensitivity, and quality of liquid chromatography with tandem mass spectrometric (LC-MS/MS) analytical systems and assays. Dr Grant has been awarded 100 patents and received both the MSACL Distinguished contribution award and ASMS AL Yergey “Unsung Hero” Award in 2024 for his contributions to Clinical Diagnostics using Mass Spectrometry. Relevant Financial Disclosures (within past 24 months, reported on Apr 23, 2026) Committee/Board/Advisory Board BCal Diagnostics Stock/Bonds Labcorp Salary Labcorp Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Numerous technologies are now commercially available that facilitate the collection of human blood samples in locations away from the clinical setting. This approach is termed patient centric sampling, or microsampling and can involve the collection of samples from a finger stick, or from elsewhere on the body. The samples can be dried or liquid and are often a smaller volume than those obtained by traditional phlebotomy. The use of these approaches potentially enables samples to be collected from currently underserved communities (pediatric, elderly, remote areas, etc). Furthermore, the approach may enable more regular sampling of individuals to be performed and facilitates choice for the patient about how and where samples will be collected. These technologies also have the potential to overcome the discomfort, pain and fear that is encountered by many when collecting samples by traditional phlebotomy. However, there are challenges around the regulatory status of the sampling devices and assays developed for clinical diagnostic purposes using these technologies. Following last year’s initial discussions on this topic, progress has been made. This workshop will take part in a facilitated discussion on what the regulatory challenges have been overcome and new challenges that have emerged. Different regulatory frameworks and quality systems will be discussed relative to EU (Medical Device Regulation + In Vitro Diagnostic Regulation), USA (FDA class 1 & 2 test “systems”) and Canada (Medical Device Directorate, ICH M10). Exemplars will be discussed relative to current products and workflows that have achieved regulatory approval in these jurisdictions. Participant discussion will then focus on how these barriers may be overcome and what future activities might be required to enable this. 2598

Thursday 745 845

Discussion Group : CAC Working Groups – What are they, why they matter, and how to get involved @ Outremont 5 Melissa Budelier, PhD TriCore Reference Laboratories Dr. Budelier is the Section Chief and Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. She is also the CLIA laboratory director of TriCore's core laboratory. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Committee/Board/Advisory Board Roche Diagnostics, Greiner Bio-one, Siemens- Healthineers Royalty / IP / Other Income Washington Univ - Patents (Methods for Detecting Neurofilament Light Chain in Plasma and Cerebrospinal Fluid; Multiplexed Assay for Amyloidosis Disorders); Tech licensed by WashU to C2N Dx Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Summary In 2026 the MSACL Compliance and Accreditation Committee is forming several new Working Groups (WG) to help clinical mass spectrometry laboratories tackle compliance, quality and training challenges. These groups focus on creating practical resources to support accreditation, regulatory compliance, quality management, and workforce development. We’re gathering input from the MSACL community to identify gaps and prioritize projects. Future outcomes from these workgroups may include but are not limited to continuing education sessions; white papers; position statements; publications; templates for quality and compliance procedures, policies, and job aids; quality management software discussions; implementation and accreditation case histories. The session will include a brief presentation, followed by Q&A and discussion. Topics to be covered include: Update and overview of each CAC workgroup Current WG membership, expectations for members, and how to get involved Projects in progress in 2026 Projects planned for late 2026 and 2027 Wish list for programs and materials from attendees – where are the gaps? 2771

Thursday 745 845

Discussion Group : Lowering the Threshold for MS-based Spatial-omics on FFPE Tissue Sections Aligned with Pathology’s Daily Practice : What to Expect? @ Outremont 6 Prof Peter Verhaert, PhD ProteoFormiX Since 2024, Peter VERHAERT is part-time professor at the Department of Imaging and Pathology of the Faculty of Medicine of the University of Leuven (Belgium) and honorary professor at the Faculty of Health Sciences of the University of the Witwatersrand (Johannesburg, South-Africa). He is also affiliated to the Laboratory of Applied Mass Spectrometry at the Department of Cellular and Molecular Medicine of the University of Leuven (Belgium). Peter was full professor Analytical Biotechnology and Innovative Peptide Biology at Delft University of Technology [Netherlands; 2005 – 2016] before founding ProteoFormiX (www.proteoformix.com). His Flemish research company was a startup (now alumnus) of JLABS, the J&J Innovation Center on the Campus of Janssen Pharmaceuticals in Beerse [Belgium; 2017]. Peter is recognized worldwide as one of the pioneers in Peptidomics, Peptides in Biology being the common theme in his >35 years of research. Prior to taking up his academic position in Delft, Peter's international career already combined academic and industrial positions: He obtained an MSc in Biology (Zoology Group) and a PhD in Comparative Neurobiology at the University of Leuven, where he held a position as assistant professor [Belgium; 1983-1987]. He then took on a postdoc position at the Laboratory of Toxicology and Biochemistry in the Biology Department of the University of Waterloo [Canada; 1988]. Upon returning to the University of Leuven, he became an associate professor in Histology and Biological Mass Spectrometry [Belgium; 1988-1999]. After an industrial sabbat year at the Flemish Biotech Innogenetics in Ghent [Belgium; 1998-1999], Peter was appointed group leader Proteomics at the Dutch Pharma company Organon (now MSD) in Oss [Netherlands; 2000-2004]. His other professional activities include: • Co-founder and president of the European Pharmaceutical Proteomics Laboratories (EPPL) [2000-2004]; • Proteomics expert at the Flemish Institute of Biotechnology (VIB) [2000-2004]; • Visiting professor Biomedical Proteomics at the Biomedical Research Institute at the Faculty of Medicine of Hasselt University [Belgium; 2004-2014]; • Editor-in-chief of the Elsevier Open Access Journal EuPA Open Proteomics [2013-2016] • Co-director of the Center of Excellence in Biomedical Mass Spectrometry (CEBMMS) at the Faculty of Medicine (Clinical Sciences Department) of Lund University [Sweden; 2016]; • Honorary professor Mass Spectrometry Histochemistry at the Maastricht Multimodal Molecular Imaging Institute (M4i) of Maastricht University [Netherlands; 2017-]. Relevant Financial Disclosures (within past 24 months, reported on May 08, 2026) Honorarium/Expenses ProteoFormiX BV Committee/Board/Advisory Board ProteoFormiX BV Stock/Bonds ProteoFormiX BV Ownership Interest ProteoFormiX BV Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Discussion Topics: Brief review of different flavours of mass spectrometry based spatial –omics of FFPE samples Principle of direct (‘top-down’) spatial MS analysis with ambient MS (MALDI and DESI) Different HR MS analyzers coupled to atmospheric pressure ion sources: from TOFs to FT instruments FFPE chemistry of formaldehyde fixation physics of paraffin embedding comparison with cryo FFPE sample origin (Homo sapiens), circumvention animal model species, ethical considerations Further processing options of FFPE samples for MSI (“MSHC”) tailored to (bio)molecules to be detected proteomics (peptidomics) metabolomics lipidomics Dataset examples Data structure from MSI dataset Mass spectra: peak resolution and mass accuracy Profile and centroid mass spectrum Pre-processing : peak picking (untargeted or targeted approach) and peak aligment in MSI Normalization: TIC vs RMS Ion image : heat map color codes and color code scale bar Multivariate analysis: spatial clustering and spatial PCA Region of interest and get mean intensities values for downstream analysis from histological annotations to mean spectrum: use of imaging data for downstream analysis in a clinical context More advanced MSHC approaches: tandem MSI, ion mobility MSI,... Future (and today’s) developments: Mining rich pathology archives (well-documented FFPE tissue biobank) Conclusion: Advantages / Disadvantages; Limits / Potential 2767

Thursday 745 845

Discussion Group : Challenges and Considerations of TDM for mAbs (Monoclonal Antibodies) @ Outremont 7 Paul Jannetto, Ph.D., DABCC, FADLM, M.T.(ASCP) Mayo Clinic Paul Jannetto, PhD, DABCC, FADLM, MT(ASCP), is a Professor in the Department of Laboratory Medicine and Pathology and a Consultant at the Mayo Clinic (Rochester, MN), where he serves as the Co-Director for the Clinical Mass Spectrometry Laboratory, Clinical and Forensic Toxicology Laboratory, and the Metals Laboratory. He also serves as the Vice-Chair of Practice for Laboratory Medicine for the Department of Laboratory Medicine & Pathology. Previously, he earned his BS in Clinical Laboratory Science from the University of Wisconsin-Milwaukee and worked as a Medical Technologist for Medical Science Laboratories before entering graduate school. He then earned a Ph.D. in Pharmacology and Toxicology at the Medical College of Wisconsin. He is board-certified by the American Board of Clinical Chemistry and American Society for Clinical Pathology. His clinical and scientific interests are centered on Clinical & Forensic Toxicology, Therapeutic Drug Monitoring, Controlled Substance Monitoring, and Elemental Analysis. Dr. Jannetto is actively involved in the Association for Diagnostics & Laboratory Medicine (ADLM) where he is presently serving as President. He has held numerous positions at the national level as president-elect, secretary, and a member of the board of directors; a member of the Governance Review Advisory Taskforce; and NACB Board of Directors. Dr. Jannetto is also a member of the American Academy of Pain Medicine, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Forensic Toxicologists, The International Association of Forensic Toxicologists, and was the President of the Midwest Association for Toxicology and Therapeutic Drug Monitoring. He has over 100 peer-reviewed publications, 19 book chapters, and over 90 abstracts/presentations at various national meetings Relevant Financial Disclosures (within past 24 months, reported on Mar 06, 2026) Consultant Fees Roche Diagnostics and Thermo Fisher Scientific Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Summary Unlike small drug molecules, the monoclonal antibody therapies often lack a well-defined maximum tolerated dose, have delayed pharmacodynamic responses, and cause the formation of anti-drug antibodies. Despite these challenges, TDM has shown clinical benefits for tyrosine kinases inhibitors suggesting the potential in Oncology. This session will discuss the challenges and considerations of using mass spectrometry to measure concentrations of programmed cell death protein 1 (PD1) inhibitors (e.g. Pembrolizumab, Nivolumab, etc.), a class of immunotherapy drugs that have revolutionized the treatment of various malignancies, to minimize toxicity and maximize efficacy. 2770

Thursday 845 900

Intermission @ Foyer, Conference Level Coffee available in Montreal 1-3. 2711

Scientific Session 3

	Montreal 4 Keynote : Proteomics - Emerging Technology	Montreal 5 Spatialomics Metabolism	Montreal 6 Clinical Microbiology Applications	Montreal 7-8 DBS Analysis	Salon Bonaventure, Hotel Level Practical Training
900 920	TBA	Altered Metabolism and Treatment Resistance in Brain Cancer Patients Daniel Wahl University of Michigan Keynote Speaker	Dissecting Metabolite Signatures and Perturbed Pathways in Syphilis and HIV Co-infection Sarina Yang Weill Cornell Medicine	Optimized Extraction of Dried Blood Spots for Untargeted HILIC Metabolomics: A Factorial Comparison with Independent Confirmation Etienne Ljoni Poisson University of Iceland	Programming Analyte Specificity into Your New LC-MS Assay Patrick Kyle University of Mississippi Medical Center
920 940	TBA	... Keynote, continued ...	Urinary Tract Infection Produces an Acute Urinary Metabolomic Signature of Host Muscle-Protein Catabolism in Pregnancy Maxim Seferovic Baylor College of Medicine	Evaluating Dried Blood Spots for Dihydropyrimidine Dehydrogenase (DPD) Phenotyping: Strengths and Limitations Kevin Vandenbroucke Ghent University	... Extended Talk ...
940 1000	Metrology for accurate protein quantification and precision diagnostics Amandine Boeuf Laboratoire National de Métrologie et d'Essais Keynote Speaker	Comprehensive Multi-omics Profiling of Cancer Metabolism with Spatial Precision Kevin Hau Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Dortmund	Clinical Implementation of a Stable Isotope Dilution Lc-MS/MS Method for Beta-Lactam Quantification: Experience From a Large Academic Medical Center Ibrahim Choucair University of Kentucky College of Medicine	Advancing Rare Disease Screening: Development of a Multi-Analyte Panel in Dried Blood Spots for Expanded Newborn Screening of Treatable Neurometabolic Disorders Rebecca Ford Revvity Omics	... Extended Talk ...

Thursday 1000 1700

Exhibits Open @ St Laurent (Exhibits) 2712

Thursday 1000 1115

Poster Session #3 - Thu Odd @ St Laurent (Exhibits) All Thursday Odd-numbered posters will be attended during this poster session (#3). 2670

Thursday 1015 1105

Poster Tour #2 @ St Laurent (Exhibits) Early Career and first time attendees are encouraged to meet at the MSACL registration desk at 5 minutes prior to join a POSTER TOUR with a guiding mentor. Poster Tour Overview 2678

Thursday 1115 1215

Plenary Lecture @ Montreal 4-5 2662

Thursday 1215 1315

Lunch & Exhibits @ St Laurent (Exhibits) Lunch hosted by MSACL. If joining an Industry Petite Suite Workshop pick up your lunch in the Exhibit Hall. Alternatively, skip the Exhibit Hall lunch lines and join the Industry Workshop in Montreal 1-3 where a box lunch will be available. 2669

Thursday 1215 1315

Industry Lunch Workshop @ Montreal 1-3 Box lunch will be available in the workshop room. 2714

Thursday 1215 1315

Industry Petite Suite Focus Hours @ Outremont 7 Host Guidance: Attendees will pick up lunch in Exhibit Hall. Plan for a 30-minute speaker/discussion from 12:30-13:00. Allow attendees time to get to their next session at 13:15. 2713

Scientific Session 4

	Montreal 4 Data Science: Fresh Approaches with Modern Tools	Montreal 5 Metabolomics and NBS	Montreal 6 New Tools to Interrogate Microbial Metabolism	Montreal 7-8 Spatialomics Methods	Salon Bonaventure, Hotel Level Practical Training
1315 1335	Building Personalized Reference Intervals for Routine Clinical Tests Brody Foy University of Washington Keynote Speaker	TBA	Graph Neural Network-Enabled Discovery of Hidden Enzymes Driving Microbial Bile Acid Metabolism Min Soo Kim Pennsylvania State University	Deep Morphology Embeddings from H&E Capture Fucosylation Signatures in Triple-Negative Breast Cancer Keervani Kandala Mallinckrodt Institute of Radiology, Washington University in St. Louis	From Kit to Clinic: How to Implement LC-MS/MS Kits in the Clinical Lab Katharina Habler LMU University Hospital, LMU Munich
1335 1355	... Keynote, continued ...	Identification of Cystic Fibrosis Biomarkers Using Metabolomic and Lipidomic Approaches and Evaluation of CFTR Modulator Responses Christiane Auray-Blais Université de Sherbrooke	Pan-Repository Metabolomics Reveals Microbial Bile Acid Conjugation of 5-Aminosalicylic Acid and Other Therapeutic Drugs Vincent Charron-Lamoureux University of California San Diego	Boronic Acid Mass Tag for Spatially Resolved Glucose Detection by MALDI MSI: Application to Prostate Cancer Spheroids Justine Gatein Université de Montréal	... Extended Talk ...
1355 1415	Agentic AI for Laboratory Analytics Nicholas Spies University of Utah, ARUP Laboratories Keynote Speaker	Towards Automated Early Screening:A Reliable LC-MS/MS Assay for Plasma Lyso-GL3 as a Biomarker of Fabry Disease Kaijuan Wang Peking Union Medical College	Metabolites, Microbes, and Mobility: Oh My! Christopher Chouinard Clemson University	Rapid Screening and Spatial Lipidomics Reveal Chemotherapy-Induced Phospholipidosis and Lipid Metabolic Reprogramming in Ovarian Cancer Stefania Maneta-Stavrakaki Imperial College London	... Extended Talk ...

Thursday 1415 1530

Poster Session #4 - Thu Even @ St Laurent (Exhibits) All Thursday Even-numbered posters will be attended during this poster session (#4). 2677

Thursday 1530 1630

Exhibitor Feedback Meeting @ Westmount 6 Exhibitors are invited to join MSACL Admin to provide feedback on MSACL 2026 and begin planning for MSACL 2027 in Montreal (September 26 - October 1, 2027). 2676

Scientific Session 5

	Montreal 4 Metabolomics - Breath analysis	Montreal 5 Toxicology	Montreal 6 Spatialomics Data Integration	Montreal 7-8 Proteomics - Other	Salon Bonaventure, Hotel Level Practical Training
1530 1550	Breath as a Diagnostic Fluid: Is It Finally Ready for Prime Time? Jane Hill University of British Columbia Keynote Speaker	Mass Spectrometric Identification of Tranexamic Acid in Cerebrospinal Fluid Following Accidental Intrathecal Administration Hannah Brown Hennepin Healthcare; University of Minnesota	Profiler and IonScell: An Integrated Open-Source Ecosystem for Omics Analysis and Single-Cell Mass Spectrometry Imaging Yanis Zirem Laboratory Prism Inserm U1192	High-Resolution Mass Spectrometry Detection of CSF-Restricted Oligoclonal Immunoglobulins in Paired CSF and Serum for Multiple Sclerosis Diagnosis Ruben Y. Luo Stanford University	Tips and Tricks for Developing Tests for the Quantitation of Therapeutic Monoclonal Antibodies Paula Ladwig Mayo Clinic
1550 1610	Identifying a Breath Volatile Signature for Parkinson’s Disease: The Panorama Pilot Study Ilaria Belluomo Imperial College London	“Goldilocks” in Bioanalysis of Hypoglycemic Drugs in Human Serum or Plasma by LC-MS/MS Julie Ray ARUP Laboratories	A Workflow for Multimodal Analysis of Mass Spectrometry Imaging and Pathology Foundation-Model Feature Maps Amoon Jamzad Queen's University	Grossly Intact: Comparing Internal Standards in a Multiplexed Protein LC-MS/MS Assay Rebecca Treger University of Washington	... Extended Talk ...
1610 1630	Translating Asthma Breath Markers into an Actionable Clinical Tool for Personalized Medicine Pierre-Hugues Stefanuto Liège University	Validation of a Comprehensive Drug Test by High-Resolution Mass Spectrometry Gillian Rexroad University of California San Francisco	Spatial Metabolomics Reveals Signatures that Differentiate Human Ductal Carcinoma in situ from Invasive Breast Cancer Natasha Iaboni Queen's University	From Collagen Fragments to Molecular Signatures: A Targeted LC-MS/MS Profiling Approach Justine Demeuse University of Liège	... Extended Talk ...

Thursday 1630 1700

Tea Break @ St Laurent (Exhibits) ALL POSTERS TO BE REMOVED DURING THIS BREAK. 2663

Thursday 1700

Exhibits Close @ St Laurent (Exhibits) Booth STAFF : Please follow this timetable to avoid disruptions to scientific sessions. 17:00 - 23:00 Breakdown 17:05 - 17:55 Box Move-In Priority LARGE (via Reception ONLY) 17:55 - 18:45 Box Transit PROHIBITED 18:45 - 23:00 SMALL-MID Box Move-In/Out (via Admin Hall ONLY) 21:00 - 23:00 LARGE Box Move-In/Out 2684

Scientific Session 6

	Montreal 4 CLOSED Session CLOSED	Montreal 5 Lipidomics	Montreal 6 Data Science: From Instrument to EMR	Montreal 7-8 Proteomics - Spatial	Salon Bonaventure, Hotel Level Practical Training
1700 1720	CLOSED	TBA	Interference or Artifact? Decoding Ambiguous Ion Ratios in Clinical LC-MS/MS Stacy Dee Labcorp	Spatially Informed DBSI-MALDI Analysis Reveals Reproducible Microstructure-Molecular Associations in Prostate Cancer Jose Marcio Luna Washington University in St. Louis	Updates from C62 - the New Third Edition Brian Rappold LabCorp
1720 1740	CLOSED	Bypassing Culture: Rapid Screening of Group A Streptococcal Pharyngitis Michael Chen The University of British Columbia	A Unified Web-Based Automation Tool for Conversion of Mass Spectrometry Result Files to LIS-Compatible Format Amir Karin Vancouver General Hospital	Deep Mass Spectrometry Profiling of 10,000+ Protein Groups in FFPE Tissue Unlocks Novel Functional Tumor Biology, Biomarkers, and Targets from Archived Samples Kate Gallagher Sapient	... Extended Talk ...
1740 1800	CLOSED	Rapid Chromatography-Free Mass Spectrometry for High-Throughput Metabolomics and Lipidomics Across Diverse Biological Matrices Felix Schmauder Bayer AG	MRMpipe Software for Clinical LC–MS/MS Analysis: Multi-Site Validation on 1,595 Samples Across 8 Hospitals and Six Clinical Cohorts Peter Kubiniok Quantivum	Defining the in vivo 3D Proteome: Plasma Protein Structural Signatures for Alzheimer’s Disease Diagnosis John Yates Scripps Research Institute	... Extended Talk ...

Thursday 1800 2030

Team Trivia Dinner with Poster Awards @ Montreal 1-4 All MSACL attendees are invited to this interactive, celebratory dinner. There is no additional sign‑up or fee required; however, seating is first-come, first-served. Form a team with your tablemates and test your esoteric knowledge in a classic pub-style trivia game! If you prefer to dine off‑site, you are welcome to enjoy a drink in the foyer before meeting up with your dinner group and heading out. 2691

Thursday 2030 2330

MSACL Networking Lounge @ Salon Bonaventure, Hotel Level All attendees are welcome to close out the evening in Salon Bonaventure. MSACL will host snacks and drinks (drinks require tokens - pick up tokens at the door or from MSACL Staff). Drinks will be available through 11:30pm. The Lounge includes a pleasant outdoor patio along a stream and among trees and shrubbery, which may be enjoyable should we have nice weather. Must be wearing your badge to attend. Prepare for karaoke! 2692

Friday

Friday 700 900

Mount Royal Kondiaronk Belvedere Challenge @ Salon Bonaventure, Hotel Level 3 mile round trip run/walk. 554 ft elevation gain. Check-in at 7:00 am for water, coffee, bananas. Group photo at 7:10 then we will proceed down the elevator. Run/walk commences at 7:15-7:20. 2693

Friday 800 930

Breakfast @ Montreal 1-4 All attendees are welcome to partake of a hearty breakfast and closing seminar before departure. 2695

Friday 915 1115

Closing Plenary Seminar @ Montreal 5 Gary Patti, PhD Washington University in St. Louis Relevant Financial Disclosures (within past 24 months, reported on Jan 22, 2026) Not yet reported. Randall Julian, PhD Indigo BioAutomation Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to automatically analyze data from laboratories world-wide. Indigo's technology also drives new stand-alone medical devices, bringing advanced data analysis to every level of the clinical lab. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue. Relevant Financial Disclosures (within past 24 months, reported on Feb 27, 2026) Stock/Bonds Indigo BioAutomation, Inc. Salary Indigo BioAutomation, Inc. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED. Yes, it is ok to arrive in your running attire. 12pm checkout time at Hotel Bonaventure. 2696